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Abstract 
            The human body is cohabitated with large number of microorganisms, which potentially influence 
the health conditions of the host. Dynamic interactions between microbiome and host are critical for this 
cohabitation relationship. Among human population, the composition of microbiome shows clear 
interpersonal variations and intrapersonal plasticity, with patterns and mechanisms that are currently 
unclear. In the first part of this thesis, we explored the human microbiome variations in relation to healthy 
aging, aimed to understand if microbiome imbalance, or dysbiosis, is a common phenotype of older adults 
regardless of the age-related diseases. In the second part, we expanded our investigation on the microbiome 
plasticity to individuals with prediabetes condition, which is more common in older adults. We confirmed 
that microbiome composition in healthy adults was not significantly different based on their chronological 
age but were dramatically altered among some individuals at risks metabolic diseases. More importantly, 
we identified a concomitant change of serum cytokines and the gut microbiome among individuals, which 
imply a causational relationship between microbiome, immune system and the metabolic diseases. This 
thesis explored the microbiome variation in both healthy individuals and patients with prediabetes, 
demonstrated the development of dysbiosis under the risk for metabolic diseases, and potentially revealed 
a new microbiome-related etiology for metabolic diseases.   
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Chapter 1: General Introduction 
The human microbiome 
The human body is colonized with a plethora of microorganisms, such as bacteria, archaea, fungi, and 
viruses. There were many studies aiming to estimate the number of the different types of microbes at 
different human body sites. To date, the numbers are being revised regularly due to the application of 
different counting techniques. In the earliest study published in 1972, the author Dr.Luckey estimated1 that 
1012 bacteria colonize the epidermis and 1014 bacteria colonize the alimentary tract of an adult. This 
estimation has been revised in a most recent study, which stated that there are approximately 3.9*1013 
bacteria2 in an adult human with a body weight of 70 kg, which is close to the number of human somatic 
cells. Other microbes such as viruses and phages are believed to be present in a similar or even higher 
number than bacteria3. Meanwhile, the number of fungi in an adult is still unknown. Genes carried by these 
microorganisms are substantially more diverse than those in the human eukaryotes, and consequently 
provide high levels of functional diversity. The collection of information describing the entire habitat, 
which includes the microorganisms, the genome of those microorganisms and the information of 
surrounding environment is termed as “microbiome” 4.  
 
Microbes are present at various human body sites, such as the skin, oral cavity, intestine, and urogenital 
tract. The skin bacterial microbiome is mainly dominated by the genus of Propionibacterium, 
Staphylococcus, and Corynebacterium, depending on the skin characteristics (such as dry, moist or oily) 5. 
The most common genera in the oral cavity include Streptococcus, Gemella, Granulicatella, Neisseria,and 
Prevotella6. Lactobacillus, Gardnerella and Sneathia are the major bacteria genera found in the urogenital 
tract 7, 8. The colon is the largest contributor to the total bacterial population in hosts, and the overall number 
of bacteria in the colon outnumbers the other body sites by approximately ten to one2. Approximately 1000 
bacterial species can be found throughout the human body, and the genomes of these bacterial species 
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encode 100 times more genes than human genes9-11. Those bacteria play a role in host digestive process 
such as digesting the polysaccharides which are otherwise indigestible12 and participating in the 
development of the immune system 13,14.  
 
Today it is thought that bacterial inoculation occurs at birth upon the exposure of vaginal, fecal, and skin 
microbiota during delivery. Although there is data implying that placenta may also contain bacteria before 
delivery (these bacteria are transported from other body sites into placenta by blood cells), these bacteria 
are often in low abundant and/or not culturable 15. Early microbial colonization in the infant gut starts with 
mainly facultative aerobes from the environment, such as Enterococcus and Propionibacterium16, and the 
major population of gut microbiome quickly switches to anaerobic microbes within one week after birth17. 
The species colonizing the neonates are highly dependent on the method of delivery: Infants born vaginally 
primarily acquire their gut microbiome from the mother’s vagina while infants who are delivered surgically 
tend to carry bacteria from human skin18. The composition of the microbial community in the gut 
microbiome is highly variable during a child’s first three years of life, and then become relatively stable 
across adulthood 19.  
 
Is the microbiome composition as stable as the human genome? The answer is no. Unlike the human 
genome, there is a greater microbial variation within an individual over time. Since the bacterial 
microbiome consists of around 1000 bacterial strains, the disappearance of a pre-existing bacterial strain or 
the acquisition of a new bacterial strain can cause changes in the microbiome composition. In theory, the 
accumulation of such small changes of bacterial strains over time could ultimately alter the entire 
microbiome community in the host. However, several recent studies found that this may not be the case. 
One study showed that roughly 45% of the species were maintained in stool samples taken from the same 
individual 46 years apart 20. Meanwhile, the gut microbiome composition is quite stable over a short time  
period, based on the comparison of stool samples collected monthly and yearly from the same donor 21,22,20,23, 
if the composition is unperturbed by external influences. In addition to the gut microbiome, studies focusing 
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on other body sites also concluded that, like the gut microbiome, the skin and virginal microbiome are 
relatively stable over time24-26. 
 
Nevertheless, the microbiome is relatively stable in a person over time, with unneglectable differences 
between individuals. Such variability in the composition of microbiome between individuals is called 
interpersonal variation, 27 which describes the presence and absence of bacteria stains when comparing the 
microbiome from different hosts. The 1000 Genome Project, which sequenced the complete genomes from 
1000 individuals, demonstrated that individual has a unique genome except for identical twins28. The 
interpersonal variability of the microbiome may be partially connected to the highly personalized genome. 
However, the clear relationship between the human genome and the microbiome is still under investigation. 
Currently, we do know that functional mutations of some genes in the host will affect the microbiome 
composition 29,30. For example, Enterobacteriaceae were reported with increased abundance31 in the subjects 
carrying point mutations in Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene. 
Other genes that are known to affect the microbiome include the fucosyltransferase 2 gene (FUT2) and 
lactase gene (LCT), and their mutations affect the growth of Bifidobacterium32,33. Other than single 
mutations, microbiome interpersonal variabilities are also associated with sex34, ethnicity group 35 and 
systematic host genetic variation36. 
 
Certain environmental perturbations can cause temporal changes of the gut microbiome and sometimes 
even overwrite the genetic influences on the gut microbiome. Studies found that monozygotic twins do not 
necessarily carry the 100% same microbiome12, although their genetic background is identical. 
Geographical location is one of the major contributors to the microbiome plasticity. If twins live in two 
different counties, the difference between their microbiome is larger than twins who live together37, 
indicating that the living environment influence the gut microbiome independent of the genetic background. 
Also, the gut microbiome of immigrants quickly converges towards the microbiome of the destination. A 
recent study found that if a resident from southeast Asia relocates to the US, his/her microbiome will quickly 
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switch to a low diversity, low Prevotella, high Bacteroides type, which is considered a westernized 
microbiome type38. Diet is another big contributor to the gut microbiome plasticity. The influence of the 
diet on the microbiome can be traced back to the very early stage of life. Studies showed that babies fed 
with breast milk have very different gut microbiomes compared to babies fed with infant formula. 39 The 
reason for this is not only the nutritional differences in breast milk and baby formula, 40 but also that both 
live bacteria and immune components are found in human breast milk. 41 The influence of diet on the 
microbiome continues during childhood and adulthood. Children growing up in Europe and Africa also 
harbor different microbiomes, due to different diet components inherent to the two geographic locations. 42 
Generally speaking, animal-based diet is associated with an increase of genera such as Bacteroides, 
Alistipes, and Bilophila, whereas plant-based diet is linked to an increase of the phylum Firmicutes and the 
genera of Ruminococcus, Roseburia, and Eubacterium. 43 Switching diet for even a few days is enough to 
change the microbial composition43, and may have long-term effect on host. A report showed that weight 
gain by overfeeding systematically altered the host microbiome and physiology conditions, including 
increased inflammation and hypertrophic cardiomyopathy. 44 This report also described a potential long-
term effect that will persist even after the body weight dropped to the pre-perturbation level. Meanwhile, 
microbiome composition can also be altered during pregnancy, and is characterized by an increase of 
bacteria phyla Proteobacteria and Actinobacteria. 45 Other components, beyond the scope of this thesis, that 
may induce changes of the microbiome composition, include the usage of antibiotics and 
probiotics/prebiotics, which was also experimentally demonstrated and reviewed 46-49. In conclusion, 
studying the microbiome is complex due to the plasticity caused by the highly personalized genetic 
background, environmental influences and physiology of the host.  
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Methods to study the microbiome  
Since the microbiome is a collection of microorganisms (such as viruses, fungi, archaea and bacteria), 
specialized methods are required for each type of microorganism. Given that this thesis focuses on the 
bacterial component of the microbiome, the respective methods are introduced in the following. 
 
Culturing approaches 
The traditional approach to study the microbiome is by microbiological culture. 50,51 Depending on their 
response and requirement of oxygen, bacteria can be classified as anaerobic (growth in the absence of 
oxygen), aerobic (growth with oxygen) and facultative aerobic (growth with or without oxygen). For 
example, aerobic and facultative aerobic bacteria mainly colonize the oxygen rich environment such as 
certain areas of the human skin and oral cavity. In contrast, anaerobic bacteria normally colonize the 
oxygen-lacking environment such as the colon. Besides the different oxygen requirements, microbial 
growth is also highly dependent on the availability of nutrients. For instance, bacteria living in the gut 
utilize food ingested by the host as their major source of nutrition and bacteria living on the skin use sebum 
as a source of nutrition. 52 Bacteria growth can be inter-dependent on each other. On one hand, there is 
competition for nutrition among bacterial species; on the other hand, bacteria are also sometimes taking 
advantage of metabolic products secreted from their cohabitants. 53,54 In summary, efforts have been made 
to cultivate the microbiome from different environmental samples. However, the reasons mentioned above 
just partly highlight how the complexity of the microbiome makes it complicated to capture the diversity 
of the microbiome using culture-based methods. As a result, it is believed that currently we are only 
culturing the tip of the iceberg and that majority of bacteria in the gut microbiome is not culturable. 55,56  
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Sequencing approaches  
Our knowledge about the bacterial microbiome is accelerated with the development of sequencing 
technologies, especially for unculturable bacteria. The first generation of sequencing is called Sanger 
sequencing, which was developed by Frederick Sanger in 1977. 57 This method is comparatively time-
consuming and costly. Hence, it is currently only used for small scale sequencing experiments. The second 
generation of sequencing technology (Next Generation Sequencing, NGS) utilizes fluorescently-labelled 
deoxy-ribonucleotide triphosphate (dNTPs) to label the DNA nucleotide and can determine the sequence 
of millions of DNA strands simultaneously through detecting the fluorescent signals. 58 The NGS 
technology largely increases the efficiency of DNA sequencing and is currently used as the method for the 
large-scale genomic sequencing projects. 59 However, both the first and second-generation sequencing 
techniques are not designed for reads longer than 1000 base pairs (bps). 58 Therefore, the shotgun 
sequencing method was developed for sequencing long DNA strands, by breaking down long DNA 
sequences into smaller fragments that can be sequenced separately, and assembly though computational 
methods to yield the overall sequence. This shotgun-sequencing method can be combined with either first 
or second-generation sequencing technique for long reads sequencing.  
 
The sequencing processes are routinely used nowadays. Once an environmental sample (e.g. fecal matter, 
skin swab, soil) is collected, the total DNA is extracted and sequenced. To determine the possible origin of 
each sequencing read, the data is aligned to the genome database, which contains DNA reads associated 
taxonomy information. The current databases which are widely used include Ribosomal Database 
Project(RDP, https://rdp.cme.msu.edu/), 60 SILVA ribosomal RNA database (https://www.arb-silva.de/) 61 
and National Center for Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.gov/). 62 Sequencing 
the entire genetic material extracted from an environmental sample is called metagenomic sequencing, 
which is one of the most widely used sequencing method for microbiome research when combined with the 
shotgun method. This method is named the whole metagenome shotgun (mWGS) sequencing. 63  
7 
 
 
In addition to sequencing the total genetic material, we can also sequence bacterial “name-tag” genes to 
obtain taxonomy information for the bacterial microbiome. Within the bacteria genome, there is a region 
of about 1500 base-pairs (bps) called “16S ribosomal RNA (rRNA) gene”. Most part of this gene is 
conserved, because any detrimental mutation of it will lead to the death of the bacteria. 64 and only nine 
small regions can bare mutations. Meanwhile, this gene can be found in almost all the bacteria species. The 
DNA sequences of the nine variable-regions (also called 16S rRNA gene V1~V9 regions) contain enough 
information to distinguish bacteria at species level. 65 Thus, the 16S rRNA gene has been used as a label 
gene for bacteria taxonomy identification. 66,67 The first application of 16S rRNA gene as a bacteria 
taxonomy marker can be traced back to 1977, when Woese and Fox used the 16S rRNA to understand the 
phylogenetic relationship of the prokaryotic domain. 68 
 
However, both the mWGS and 16S rRNA sequencing methods have limitations. Although the mWGS 
sequencing can generates the most comprehensive information, it lacks a computationally easy and accurate 
method to obtain the microbiome taxonomy composition. 69,70 Moreover, mWGS costs nearly four times 
more than 16S rRNA sequencing for one sample. The major advantage of the 16S rRNA gene sequencing 
is the low cost with a focus on bacteria taxonomy. Also, it requires a lot less bacterial DNA to reconstruct 
the microbiome composition compared to mWGS. However, there are three major limitations of the 16S 
rRNA sequencing method: 1) Since the interpretation of bacteria taxonomy largely relies on the accuracy 
of the existing database, the taxonomy estimation cannot be confidently confirmed if the bacteria species 
have not been cultured and sequenced previously. 2) Bacteria may contain multiple copies of the 16S rRNA 
gene, so the quantitative comparison of bacteria taxonomy based on 16S rRNA gene reads count may not 
be accurate. The fold-changes of 16S rRNA gene reads of a certain bacterial species may not reflect the 
biological quantitative fold-change of the bacteria cell when compared by samples. 3) The preparation of 
the 16S rRNA sequencing library involves a polymerase chain reaction (PCR), which may introduce bias 
on certain bacteria species depending on the selection of PCR primers [data from unpublished papers at 
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Weinstock Lab]. Thus, when interpreting results from a 16S rRNA sequencing based experiment, these 
limitations need to be taken into consideration.  
 
Analysis of Microbiome data 
Statistical Analysis of Richness and Diversity 
Once the sequencing data is obtained, there are several processing steps before the data can be used for 
biological interpretation. The methods will be described in detail in the method section of this thesis. Briefly, 
the 16S rRNA reads are being clustered by their nucleotide sequence similarity. In general, if 97% of the 
reads are identical, they will be clustered together. 71,72 When all sequencing reads are assigned to different 
clusters, a representative read for each cluster is identified (normally the representative read is the read that 
appears the most within a cluster). Then these representative reads are aligned with existing reads in the 
online database for taxonomy identification. These clusters are not exactly equal to a biologically defined 
genus or species, hence they are called “Operational Taxonomic Unit (OTU)” 73 At the end, one table is 
formed with the information of how many reads are assigned to each OTU (Figure 1.1a: example of an 
OTU table), and another for the taxonomy information of each OTU (Figure 1.1b, example of a taxonomy 
table).  
 
After the OTU table is generated, it can be used for the comparative analysis. If one sample contains more 
reads that belong to a given taxa, then this sample contains more bacteria from such taxonomy. However, 
before this assumption can be made, the difference of total sample reads (also called sequencing depth) 
needs to be taken into consideration. Thus, a table illustrating the normalized proportion of reads belonging 
to each OTU is formed, which is called the relative abundance table (Figure 1.1c, example of a relative 
abundance table). This is simply calculated by the number of reads in each OTU divided by the total reads 
of a given sample.  
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Figure 1.1 Example of Microbiome data
Figure 1.1. Example of Microbiome data
a) Example of an OTU table, number indicate the reads count belonged to each OTU 
in each sample. 
b) Example of a Taxonomy table.
c) Example of a relative abundance table, the number indicate the fraction of reads 
that belonged to each OTU. The column (each person) should have a sum of 1. 
Sample 1 Sample 2 Sample 3
OTU_1 15 10 0
OTU_2 5 0 0
OTU_3 0 20 35
OTU_4 5 5 5
phylum class order family genus
OTU_1 Proteobacteria Epsilonproteobacteria
Campylobacter
ales
Campylobacte
raceae
Campylobacte
r
OTU_2 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides
OTU_3 Fusobacteria Fusobacteriia Fusobacteriales Fusobacteriac
eae
Fusobacterium
OTU_4 Bacteroidetes Bacteroidia Bacteroidales Prevotellacea
e
Prevotella
Sample 1 Sample 2 Sample 3
OTU_1 0.6 0.29 0
OTU_2 0.2 0 0
OTU_3 0 0.57 0.88
OTU_4 0.2 0.14 0.12
a. Example of OTU table
b. Example of Taxonomy table
c. Example of Relative abundance table
10 
 
 
Since the microbiome is an ecological community of microorganism, there are ecology parameters to 
describe the characteristics of this community. The most widely used ecology parameters are richness and 
diversity. 74 Richness simply describes how many unique taxa are present in a community. Measurements 
of richness include observed species index, which measures how many OTUs can be formed from one 
sample, and Chao 1 richness (Figure 1.2). There is slight difference between the two parameters in that if 
an OTU has a low prevalence (can only be found in one sample or two samples), Chao 1 richness does not 
consider it as a “real” OTU, and these OTUs will be removed from richness estimation. 75,76 
 
If a species is very dominate in the community (for example, 70% of the reads are contributed by one 
species), the biological influence of this species might be more significant than others. However, the 
richness index cannot be used to distinguish the more dominate species from the less dominate species. In 
order to take the species dominance into consideration, ecological diversity indexes such as Shannon 
diversity and Simpson Index are used. The equations for the two indexes are shown in Figure 1.2. 77-80 
Shannon diversity weights the proportion of each species by adding a natural logarithm of the relative 
proportion, and Simpson diversity index weights the proportion of each species by adding a square of the 
relative proportion value. Mathematically, rare species that do not have high relative abundances will not 
greatly impact the index. Another index, which is called Renyi index (formula showed in Figure 1.2 81),  
adds another parameter, the q-value, to measure the ecological diversity. When the q-value increases, a 
higher mathematical weight is given to the dominant species. As a result, how sharply the Renyi index 
decreases with the increase of q-value (the slope of the curve) describes the evenness of a community 
(Figure 1.2). If the Renyi index measurements decrease sharply when q-value increase, it means this 
community is very skewed. 82 
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Shannon Diversity
Simpson Index
Renyi Diversity
Figure 1.2. Equations of Diversity Index
pi is the proportion of individuals belonging to the i th
species in the dataset of interest, R is the actual number of 
species (observed species).
Figure 1.2. Equations of Diversity Index
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Statistical Analysis Based on Distance Matrix 
Dissimilarity is a measurement of how similar (or dissimilar) two communities are. The index of 
dissimilarity can also be applied to microbiome communities. One of the most widely used dissimilarity 
indexes in microbiome research is called the “Bray-Curtis” Distance. This method was developed to 
quantitatively compare the ecological similarity of forest around Wisconsin. 83 It uses count data to generate 
a score of dissimilarity based on two calculations: total number of species in each community and number 
of species that are shared by the two communities. When each microbiome sample is considered a bacterial 
community, Bray-Curtis dissimilarity can be calculated for any pair of microbiome samples. The “UniFrac” 
distance is an alternative to Bray-Curtis distance, 84 it factors the phylogenetic relationships between 
members of a community. For example, if Community A has 2 fish, 2 birds and 3 mice, Community B has 
2 fish, 2 birds and 3 rabbits, Community C has 2 fish, 2 birds and 3 flies. The Bray Curtis dissimilarity 
index will determine that the distance between Community A and B is the same as the distance between 
Community A and C, but the UniFrac distance will determine that the distance between Community A and 
B is smaller than the distance between Community A and C. This is because mice and rabbits are 
phylogenetically more similar than mice and flies. However, the accuracy of UniFrac distance is largely 
based on obtaining an accurate phylogenetic distance, 84 which is not computationally straightforward when 
hundreds of taxa are involved.  
 
Statistical Analysis based on Principal Component Analysis and Principal Coordinate Analysis 
When pairwise dissimilarity scores are generated between microbiome samples, one way to visualize the 
total variance of all samples is to perform a principal component analysis (PCA). PCA displays high 
dimensional data using two major components by mathematically transforming high dimensional data into 
two dimensions, while still maintaining the majority of relative dissimilarity between samples. The two 
components are usually set as X axis and Y axis in a scatter plot, with an annotation of the variance that 
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each axis explains. If the dissimilarity is calculated beyond the Euclid coordinates, then this method is 
generalized to principal coordinate analysis (PCoA). The PCA and PCoA are usually used as methods for 
exploratory analysis in order to generate a graphical overview of the entire data from a project. To 
statistically test if the two groups are forming different clusters, a test such as Permutational multivariate 
analysis of variance (PERMANOVA) or analysis of group similarities can be used. 85 
 
Statistical Analysis based on Linear Discriminant Analysis (LDA) 
In the microbiome research, PCA and PCoA are mainly used for visualization of the relationship between 
microbiome samples, additional analysis is required for a deeper understanding of the data, especially 
differences on single taxonomy level. For example, if the microbiome from stool samples and from saliva 
samples show two clusters on a PCA plot, then the next question is to identify the bacteria that are 
responsible for this result. Linear Discriminant Analysis (LDA) is one of the widely used methods for this 
purpose. 86 To use this method in above example, each sample needs to be labeled either “stool” or “saliva”, 
then each bacteria taxonomy unit within a sample will be examined and obtain a score called “linear 
discriminant score”. 87 This score is a mathematical summary of the relative abundance differences between 
the two population. The way in which each sample need to be labelled for identifying the differential-
abundant species is called “supervised analysis”. 88 
 
Statistical Analysis based on Machine Learning 
Machine Learning is a collection of newly emerged methods for pattern recognition and data modelling. 
This collection of methods can also be applied to the microbiome data, especially 16S rRNA data. For 
example, if we want to determine the species that are differentially abundant in stool and saliva sample, we 
could use traditional statistical methods such as nonparametric test or LDA. However, these methods 
usually make stringent pre-assumptions about data distributions or sample sizes. Nonparametric tests do 
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not have the same statistical power as the parametric tests, which generally means that more samples are 
needed for a comparison. Also, nonparametric tests will generate large false positive signals when multiple 
tests are performed. Similarly, LDA analysis is not designed for a small sample size or zero-inflated data 
(indicating that when the data contains many zeros). 89 Thus, the machine learning methods may be an 
alternative to the traditional statistical methods. Here, I will introduce one of the currently used, supervised 
machine learning method: Random Forest (RF). An application of RF will be described in Chapter two. 
The concept of RF involves using a given taxa to determine the class of a sample. For example, if we 
hypothetically know from our existing data that OTU X is more abundant in stool samples than in saliva 
samples, then when a new sample arrives, we only need to measure whether this sample contains a high 
level of OTU X to determine whether this sample is a stool sample or a saliva sample. This OTU X is named 
an “important” OTU by the method because it has the power to categorize the sample. In microbiome 
analysis, the purpose of building the RF model is often to determine which OTU is important. For each 
OTU, we will randomly rearrange the class of each sample, and measure if using this OTU we can still 
determine the class of a given sample. If the random rearrangement process does not decrease the predicting 
accuracy of this taxon, then it is not important. The mean-decrease-accuracy (MDA) score is used to 
describe how important a given OTU is for determining the sample class.  (Figure 1.3) 
 
In summary, I provided an overview of human microbiome research in this section; stated the benefit and 
limitations of using the 16S rRNA gene to study the microbiome; described the structure of the microbiome 
data; and explained how statistical parameters can be used for the data analysis.  
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Figure 1.3. Random Forest
Blue table is the ”original” distribution, yellow table is the “randomly rearranged” distribution. 
When sample label are randomly rearranged , the OTU_X cannot be used to accurately distinguish 
sample class, this means OTU_X is “important”. 
Figure 1.3
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Animal Models for Microbiome Research 
The importance of the microbiome in immune response has been demonstrated by studies using different 
animal models. Therefore, I am going to introduce several animal models. The “germ-free” mouse is a 
typical animal model since these mice are maintained in a germ-free environment and does not carry any 
bacteria. The history of developing the germ-free mouse model can be traced back to the year of 1939. 90 
This animal model made many important discoveries possible, especially early experiments that 
demonstrated the causational role of the microbiome in many phenotypes. For instance, studies found that 
germ-free mice do not develop intact immune systems. They have increased activities on type 2 helper T 
(Th2) cells 91 and decreased activity of type 17 helper T (Th17) cells 92 compared to the wildtype mice. 
Researchers also observed that the germ-free mice showed an impaired immune response against viral 
infection. 93 These observations imply that the gut microbiome is required for the development and accurate 
functioning of the immune system, at least in mice.  
 
Transgenic mouse models are also widely used in the microbiome studies. The manipulation of certain 
genes in mice allows to address how the expression of these genes or the lack thereof are affecting the 
composition of microbiome. For example, Toll like receptor 5 gene (TLR5) plays an important role in host 
recognition of bacterial flagellin. The knockout of the TLR5 gene in mice will lead to gut microbiome 
changes and host phenotypes such as metabolic syndrome, 94 decreased host immune response against 
influenza viral infections, 95 and impaired bone tissue material properties. 96 The usage of transgenic animal 
models can help dissect the specific gene-microbial interactions and the impact of such interactions on host 
physiology.     
 
Another widely used model is mice fed with different diets. Since diet has a substantial influence on the gut 
microbiome, changes in components of diets often alter the gut microbiome composition of mice. The 
correlation between diet and microbiome composition can be established by comparing host microbial 
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compositions before and after the switch of diet. The measurements for host physiologies (such as serum 
glucose level and BMI) can provide biological relevance associated with such diet-induced microbial 
alterations. One famous study from Jeff Gordon’s group showed that feeding mice with a high fat diet (HFD) 
will induce obesity and lead to a microbiome alteration. 97 The study also confirmed that the microbiome 
associated with the HDF is the cause of obesity, in addition to the excessive nutrition in the food. When the 
microbiome was transferred from obese to lean germ-free mice, the germ-free mice became obese without 
the HDF diet. Five years later, a follow up study from the same group confirmed that the causational effect 
of microbiome on obesity also exist when the human fecal samples are transferred to mice. 98 It is 
hypothesized that the HFD will cause an overgrowth of certain bacteria species, and thus increase the ability 
for the gut microbiome to supply energy to the host. 99 This obesity-associated microbiome type is also 
linked to inflammation in the gut 100 and is proposed as one of the etiologies of Inflammatory Bowel Disease 
(IBD) 101,102 and Type 2 Diabetes. 103 
 
A deviation of the normal microbiome composition is called “Dysbiosis” and is potentially harmful to the 
host. This harmful stage does not necessarily involve an overgrowth of any pathogenic species. 101,102 The 
precise definition of dysbiosis and the associated species is still under debate and development. Currently, 
dysbiosis is usually used to describe an altered microbiome composition that is associated with a disease 
type, such as dysbiosis with IBD, or dysbiosis with Type 2 Diabetes. 104,105 
 
Using animal models to study the microbiome has benefits and limitations. The major benefit is the 
possibility for manipulating and controlling genetic and environmental background. As mentioned before, 
it is ethically impossible for humans to be born in a germ-free environment but is feasible for mice. 
Meanwhile, it is more practical to manipulate certain gene expressions in mice when studying the gene-
microbial interaction. Meanwhile, perturbations such as fecal microbiome transfer (FMT) are much less 
risky to perform in mice than in humans. 106 When correlational relationships are observed between 
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microbial components and disease phenotypes, the application of FMT will allow researchers to examine 
the causational relationships of this observation. 
 
However, limitations of using animal models to study the microbiome should not be neglected. The 
physiological differences between mice and humans should always be considered. The initial usage of mice 
as a genetic model to study human biology was based on the idea that 95% of human genes can be traced, 
at least as an isotype, in mice. 107 However, the story in the microbiome research might be different. 
Although the microbiome on phylum level is quite similar between mice and humans, 108 taxonomic 
differences are quite large on species level. 109 Nevertheless, the loss of genetic diversity in experimental 
mouse models may cause issues for gut microbiome research. For example, a commonly used mouse model 
C57B/6J is known to carry a mutation on a gene that encodes phospholipase A2 (PLA2) enzymes, 110 which 
potentially modulates the gut microbiome composition since this enzyme serves as an anti-microbial 
peptide. 111 In fact, diversity outbred mice (which have a mixed genetic background) are now proposed for 
population level microbiome research. 112 
 
Current Datasets for Human Microbiome Research 
After the NGS became available, there were several large studies carried out in order to get an understanding 
of the human microbiome on a large scale. In the last part of this introduction, I will describe several famous 
datasets and their major findings to provide an overview of the human microbiome research.  
 
The Human Microbiome Project (HMP): 
The Human Microbiome Project (HMP) funded by National Institution of Health (NIH) is one of the earliest 
projects that focused on understanding the composition and variance of human microbiome. This project 
has two phases. The overall goal for this project is to establish a general understanding of microbiome in 
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the human population, as the majority of the previous studies were based on microbiology culture. The first 
phase of HMP started in 2008. It included 242 healthy subjects who had been sampled for 15 (male) or 18 
(female) body sites, which include Gut, Airway, Oral cavity (9 samples), Skin (4 samples), and Vagina (3 
samples, female only). This project generated both the microbiome 16S rRNA data (2,971 samples with 
V1~V3 region and 4,879 samples with V3~V5 region) and the mWGS data (749 samples, 5,140,472 total 
non-redundant gene counts from 11.7Gb of sequencing data). 113 This project also generated approximately 
2,200 microbial isolates whole genome sequences. In 2017, a supplementary study9 provided 2103 samples 
with mWGS data from 252 additional subjects. The first phase of HMP provided an excellent overview of 
the human microbiome and archived a set of high-quality sequencing data for hypothesis testing studies.   
 
The second phase of the HMP project was named “The Integrative Human Microbiome Project” (iHMP), 
which was started in 2014 and is still in the data-analysis phase.114 This is an additional effort integrating 
multiple host "omics" with microbiome data in a longitudinal manner. The theme of iHMP is more disease-
related compared with first HMP phase. There are three cohorts collected under this project in order to 
understand the role of the microbiome 1) during pregnancy and onset of preterm birth, 2) on IBD 
development, 3) on the early stage of Type 2 Diabetes (T2D) development. The study of the third cohort is 
leaded by Weinstock group at The Jackson Laboratory in collaboration with the Snyder group at the 
Stanford University. The data generated from this cohort will be used in the third chapter of this thesis. 
 
The Metagenomics of the Human Intestinal Tract (MetaHIT) 
The European initiative MetaHIT project involves eight countries and 13 research centers, which was 
funded by the European Commission in 2008. The goal for this project was to establish a gene catalog for 
microbial genes, and mainly focused on the gut microbiome. Similar to the result from HMP, they initially 
identified 3.3 million different genes in 576.7 Gb of sequencing data from 124 individuals, 11 and later 
expanded this number to 9.8 million genes from 249 additional samples. 115 The MetaHIT consortium also 
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has a general interest in bacteria related to Inflammatory Bowel Disease (IBD) and obesity in addition to 
characterizing the microbiome in healthy people. One major discovery of this project is that inter-individual 
dissimilarity of the gut microbiome could be summarized into three clusters, termed as “Enterotypes”. 116 
The formation of clusters is not a result of gender, age, or BMI but does show some clinical significances. 
116,117 The Enterotypes were also reported from HMP two years after the first enterotype discovery. 118 
Another finding is that the ecological richness of the human gut microbiome is an indicator of host 
metabolic profiles. 119 
 
The 500 Functional Genomics Project (500FGP)  
The 500 Functional Genomics Project aims to understand the interaction between host genomics, host 
microbiome and host physiological phenotypes. This project started in 2013, with participants from the 
Netherlands, Romania, Tanzania, Indonesia and Brazil. The cohorts recruited in this project include 
individuals with obesity, HIV, gout, fungal infections, Lyme disease, diabetes, and autoimmune diseases. 
Different from the iHMP, this project used a cross-sectional design, which means only one time point was 
included for each participant. This project systematically compared the relationship between host genetics, 
serum cytokine level, season, sex, age and the gut microbiome composition. 30,120,121 There are several major 
findings from this project. It reported that microbial palmitoleic acid metabolism and tryptophan 
degradation to tryptophol was linked to proinflammatory cytokine production, 122 and high fat diet was 
triggering the proinflammatory cytokines production through NLRP3-Dependent innate immune pathways. 
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Thesis Objective 
The purpose of this thesis is to begin an initial exploration of how the microbiome may be altered with 
healthy aging and whether microbiome dysbiosis reflects the onset and progression of chronic disorders of 
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aging, specifically prediabetes. By exploring the microbiome variation in both healthy and disease 
conditions, we aim to gain a better understanding of how microbiome composition is linked to host 
physiologies and health conditions. Additionally, we will explore the overall hypothesis that the altered 
microbiome composition in individuals with certain cytokine profiles could be a sign of the microbiome 
dysbiosis, which are related to the onset and progression of metabolic disorders.  
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Chapter 2 
Background 
In this chapter we will present a comparative study of the microbiome of young and older adults. We use 
this study as an example to outline experimental design and computational methods for conducting studies 
on the human microbiome. Our overreaching hypothesize is that the microbiome in older adults show signs 
of dysbiosis such as lower ecological richness and higher number of harmful bacteria. Here we present a 
cross-sectional study with the goal of determining if the microbiomes of young and older individuals are 
significantly different and to illustrate those differences. The results of such a study will help address the 
myriad of health issues associated with age. We further postulate that investigating microbial composition 
at the two poles of the natural human health condition would lend insight into the direct and indirect 
relationships that commensal bacteria have with their hosts. Additionally, we postulate that the effects of 
the variables which complicated interpretation of the study on microbiome plasticity discussed in chapter 
1, will be minimized in this study as both groups are starkly different in terms of age but not designed to be 
biased for other variations. We hope to reduce the background noise of microbiome variation in this way. 
Although our analysis of this study identified several microbes associated with age, our analysis revealed 
that even in small studies comparing two very different groups, human microbiome studies can require 
many subjects in order to obtain significant statistical power to draw confident conclusions.  
 
Chronological age may affect microbiome composition. Advanced age is associated with a wide range of 
changes in physiology, biology, behaviors, as well as social status, and each of these variables can influence 
microbiome composition to varying degrees. For example, the aged population generally has altered eating 
habits, reduced physical activity, 124  slow gut motility, 125 immune deficits, 126,127 and a decline in gut stem 
cell regenerative capacity. 128 These age-related characteristics in old subjects may collectively alter basic 
biological processes in different tissues, thus influencing both microbial composition a well as the 
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biological responses influenced by the microbiome. 129 Before looking into any causational connection 
between age-related diseases and microbiome changes, we must understand if and how microbiome 
composition differs between young and old subjects. 
 
The design of a well-controlled experiment for age-related microbiome studies is faces biological 
limitations as well as technical challenges. The biological limitations mainly come from the coexistence of 
confounding factors (e.g. environmental factors) that may affect microbiome composition. This may 
undermine the conclusion of any study that only focuses on age. The ELDERMET project, one of the largest 
studies on the microbiome in the old population, pointed out that diet and living condition (such as 
geographic location and status of being institutionalized) are two major factors that influence the older 
adults’ gut microbial composition. 130-132 Additionally, age-related diseases such as IBD, 133 Alzheimer’s 
disease, 134 diabetes 135 and behaviors such as usage of antibiotics 47 could also affect microbiome 
composition. As a result, not all conclusions of the ELDERMET project may apply to old individuals 
generally. Therefore, conclusions about age-related microbiome differences should be considered together 
with the geographic location, living conditions as well as other criteria noted upon a subject’s recruitment. 
 
In addition to biological limitations, statistical challenges arise when testing age-related microbiome 
differences. Depending on the aim, comparative microbiome analyses could involve either statistical tests 
on summary statistics or statistical tests across microbial taxa. The former test if the microbiome diversity 
and richness – common indicators of community complexity – of the young subjects are different from the 
microbiome richness and diversity in the elderly subjects. The null hypothesis for such tests is that the 
microbiome richness and diversity in the young and elderly subjects are the same. On the other hand, 
statistical tests across microbial taxa compare the relative abundance of each individual taxonomy unit 
(taxonomy units can be a species, a genus or an operational taxonomy unit) generated from the 16S rDNA 
sequences and determine whether each unit is differentially abundant between the two age groups. The null 
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hypothesis is that, for a given taxonomy unit, the relative abundance of this unit in the young subjects is 
equal to that in the elderly subjects. 
 
When a null hypothesis is formed, statistical tests can be used to determine if the null hypothesis is likely 
to be true. For example, a two-sample t test can be performed to compute the probability (i.e., the p-value) 
of obtaining a more extreme t value given that two groups have the same mean of a measurement of interest 
(e.g., community richness, community diversity, or the relative abundance of a given taxonomy unit). If 
this probability is less than 0.05, the two groups are considered “significantly different”. A p-value less 
than 0.05 can be interpreted as there is a less than 0.05 chance to observe the same data if the null hypothesis 
is correct. Therefore, we reject the null hypothesis and conclude that the sample-mean, community richness, 
community diversity or the relative abundance of a taxonomy unit are not equal between the two groups. 
However, when multiple tests are performed, a more stringent cutoff value then 0.05 is required. For 
instance, if 500 OTUs are compared across numerous groups with a p-value cutoff set at 0.05, according to 
the definition of p values a total of 25 OTUs will appear “significantly different” just by chance even if 
none of the OTUs were truly different between groups. Many statistical techniques have been developed to 
control for such false positive rate, including resampling approaches such as bootstrap, p value adjustment 
procedures such as Benjamini-Hochberg, and the introduction of other significance statistics such as q 
values. In the field of microbiome studies, for the sake of simplicity, we generally reduce the p-value cutoff 
to 0.002 when multiple comparisons are present, which, in the example above, is equivalent to to an 
expectation of <1 false positive. 
 
In setting the cutoff p-value for rejecting the null hypothesis one must also consider “effect size” (measures 
how different two population are) as well as “sample size” (how many biological samples are collected). 
These statistics are used to calculate another statistic that determines if the amount of data collected for a 
specific dataset, is enough to detect a statistically meaningful difference between groups at a specified 
cutoff p value.  This statistic is termed “Power”. Power is calculated from both the expected effect size and 
25 
 
sample size across a range of significance levels. For example, if the difference between two groups is large 
(large effect size), or a less stringent significance level is set (bigger p-value cutoff), the Power statistic will 
indicate that relatively few samples are required to detect significant differences at a specified p value.  
 
Two ways to increase the statistical power of a study are to increase the sample size or to increase the effect 
size. Increasing sample size requires collecting more biological replicates for the comparison. But exactly 
how to increase effect size is not straightforward. Effect size is determined by the difference between the 
population mean of two groups and the standard deviation (SD). 136 The effect size increases when the 
difference between sample-means is increased, or if the SD is decreased. Increasing the mean difference is 
not applicable to observational studies. Therefore, either increasing the measurements accuracy and/or 
consistently selecting additional subjects for specific groups is good practice for obtaining a good power.  
 
Determining the sample size that should be used for a particular microbiome study in order for the power 
of statistical interpretations to be significant is complicated as it cannot predetermine what the distribution 
of the microbiome data will be. Based on the previous reports, several different statistical assumptions can 
be made about the data distribution, depending on the hypothesis to be tested. These include the Dirichlet 
multinomial distribution, 137,138 negative binomial distribution 139,140 and the zero-inflated Gaussian 
distribution. 141,142 Interestingly, one research demonstrated that the data distribution may not affect the 
power estimation very much when the expected difference between sample means is less than 10%. 141 To 
make a simple estimation, the power calculation in this chapter was based on a T-distribution. 
 
Due to the biological and technical challenges mentioned above, the conclusions of previous studies 
investigating how the microbiome differs between young and old groups is riddled with inconsistencies.  
For example, the percentage of Bacteroides, a major member of the human gut microbiome, has been 
reported to be higher in old adults in some studies, 143,144 and lower in others. 145,146 We attempted to alleviate 
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the inconsistencies identified in previous studies by designing more controlled experiments and using more 
dependable statistical approaches. For example, to address biological challenges, we reduced the potential 
confounding effects of disease and medication on the microbiome by selecting subjects who were declared 
disease-free and not taking certain kinds of medication that known to affect the microbiome (see methods). 
Additionally, all subjects were community-dwelling and fully-independent, thus minimizing the 
confounding effects of disability or life in an institutionalized setting. To address technical challenges in 
data interpretation, we generate a detailed power estimation for each of our analysis. The findings presented 
in this chapter will provide additional information on age-related differences in the human microbiome as 
well as provide an outline on how to design similar comparative studies regarding the human microbiome.   
Results 
Description of study design  
All studies were conducted following approval by the Institutional Review Board of UConn Health Center 
(IRB Number: 14-194J-3). Following informed consent, oral and fecal microbiome samples were obtained 
from 10 healthy young (HY, 23-32yrs, mean=25) and 13 healthy old (HO, 69-94yrs, mean=77) volunteers 
residing in the Greater Hartford, CT, USA region using services of the UConn Center on Aging Recruitment 
and Community Outreach Research Core (http://health.uconn.edu/aging/research/research-cores/). 
Recruitment criteria were selected to identify healthy individuals who were experiencing “usual aging” and 
were thus the representatives of average health conditions of the population within the corresponding age 
groups. 147 Selecting this type of cohort increases the generalizability of our studies and the likelihood that 
these findings can be translated to the general population. 147 Subjects were carefully screened to exclude 
potentially confounding diseases and medications, as well as frailty. Individuals who reported chronic or 
recent (i.e., within two weeks) infections were also excluded. Subjects could have chronic diseases but were 
excluded if the following were present: congestive heart failure, kidney disease (serum creatinine >1.2 
mg/dl in men and >1.1 mg/dl in women), diabetes mellitus requiring medications, immunosuppressive 
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disorders or the use of immunosuppressive agents including oral prednisone in doses >10 mg daily. Since 
declines in self-reported physical performance are highly predictive of frailty, subsequent disability and 
mortality, 148 all subjects were questioned as to their ability to walk. Scoring TUG > 10sec was considered 
an indication of increased frailty and resulted in exclusion from the study. 149,150 
 
Metagenomic Sequencing data Overview 
Total DNA was extracted from the samples, and a variable region of 16S rRNA gene was amplified before 
the sample are sequenced. The raw sequencing reads were being processed in bioinformatics pipeline 
described in method. There were 548 OTUs generated from the raw sequencing data. OTUs that contained 
five or less reads were removed from the data set. 381 OTUs from the saliva samples and 405 OTUs from 
stool samples were obtained. In addition, 120 young-related OTUs and 35 aged-related OTUs were found 
in saliva samples, while 39 young-related OTUs and 150 aged-related OTUs were identified in fecal 
samples. 
 
We first examined the beta dissimilarity between samples based on OTUs under unweighted UniFrac 
Distance. This method uses a phylogenetic-tree-based beta dissimilarity measurement to calculate the 
relative distance between samples. According to a permutational multivariate analysis of variance 
(PERMANOVA), age may be a significant variable (the P value is on the edge) in explaining the difference 
between gut microbiome from young subjects compare to gut microbiome from old subjects 
(PERMANOVA: Pr>(F) value=0.049). However, age could not explain the potential variation in saliva 
bacterial microbiome community when we applied the same method to analyze saliva samples 
(PERMANOVA: Pr>(F) value=0.449) (Figure 2.1a). 
 
To further understand if bacterial community structure differs regarding to the dominant taxonomies, we 
constructed a tree based on the 20 most abundant OTUs from all 46 samples (Figure 2.1b). As expected, 
28 
 
the saliva and stool samples clearly formed two distinct branches. Interestingly, the saliva sample from 
subject #107 also contained representative OTUs found in stool samples (Figure 2.1b). Among the 20 most 
abundant OTUs, we did not observe any additional branch that related to age groups. This implies that 
dominant bacterial microbiota is relatively stable across the healthy human aging process. Combined with 
the result from PERMANOVA analysis, we concluded that microbiome population may not have a dramatic 
change during aging in terms of bacteria type and abundance.  
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Figure 2.1: Overview of Microbiome Community
aPrinciple coordinate analysis of beta dissimilarity. 
Unweighted-UniFrac Dissimilarity between samples. Green dots represent saliva from young cohorts, red 
represents saliva sample from old cohorts. Purple dots represents stool sample from young cohorts, and Blue 
dots represents stool sample from old cohorts.
b) Cluster based on 20 most abundant OTU. 
“Manhattan” clustering of samples based on 20 most abundant OTUs. Color of sample labels indicate the 
biological origin of the sample. Vertical bars on the right (and color of the branch) indicate the age-group of 
each sample. Horizontal bar next to each sample label is the relative abundance of 20 most abundant OTUs, 
the annotation is on the left. 
Old
Young
Saliva
Stool
a)
b)
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Gut microbiome richness and diversity between groups 
Diversity of bacterial microbiota is an important characteristic of microbiome composition. 151 Richness 
composes a mathematic measure of the number of detected species and diversity takes the relative 
abundance of the species into account. Here we assumed each OTU to be an organism and calculated the 
richness (total number of different bacterial types present) and diversity (variability of different bacterial 
types present) for each sample.  
 
To estimate species richness, we calculated the Observed Species and Chao 1 index of our samples. The 
number of observed species in saliva samples from the old cohort was significantly lower than the young 
cohort. Although less obvious, a similar trend was observed when calculating the Chao 1 index. Observed 
Species richness in Stool from the old cohort showed a higher mean value compared to young, and Chao 1 
index showed a similar trend (Figure 2.2a). We speculated this result was due to sequencing singletons, 
which contribute more to the total variance in stool than in saliva, since Chao1 index does not take 
singletons into calculation. 76 
 
Within a microbiome community, there are “dominate bacteria” which have higher relative abundances. To 
give a higher mathematical weight on these dominate bacteria, we used Shannon entropy and the inversed 
Simpson index. Similar to the trend in species richness, Shannon entropy of saliva microbiome from the 
old cohort is lower compared to that from young cohort, and Shannon entropy of stool microbiome is 
opposite (Figure 2.2b). The measure of inverse Simpson index weights more on abundant taxonomies than 
the measure of Shannon entropy. We think this is another piece of evidence that the bacterial population 
difference between young and aged cohort resides in less abundant organisms within bacterial microbiota.  
Besides the bacterial diversity, the evenness of bacteria community is another important character of gut 
microbiome. It is a mathematical description of how different the relative abundance of each species is. 
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One way to describe it is by increasing the mathematical weight on dominate species when calculate 
diversity and observe the sequentially decreased diversity.  
 
Renyi diversity is designed to perform such a calculation. 152 When alpha-value increases, a heavier 
mathematical weight is given to more abundant organism. And the slope of the curve represents an overall 
evenness of microbial community (Figure 2.2c). Like the trends described above, significance of diversity 
difference is lost when give a higher alpha-value (higher weight on dominate species), which indicates that 
the bacterial community is more similar when only consider the most abundant organisms. This again 
confirmed that the variance between young and aged cohorts arises from organisms that are less abundant. 
 
To understand our study power on detecting the difference between richness and diversity, we simulated 
the relationship between effect size, sample size, expected significance and study power (Figure 2.2d). The 
actual effect sizes of observed richness, Shannon Diversity and Inverse Simpson index are 0.94, 0.84 and 
0.72 for saliva dataset, 0.93, 0.95 and 0.75 for stool dataset. As a result, the study power of our 
richness/diversity comparison is between 0.676 and 0.869 under a p-value equal to 0.05. This could be 
interpreted that if we accept the null hypothesis (richness/diversity are equal between groups), there is 
around 15~25% of a probability that they are not biologically equal on a given effect size. The lower effect 
size on comparing Inverse Simpson index is consistent with our result generating from Renyi Diversity 
calculation, which suggests that the more abundant species tends to be similar between two age groups.  
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a) b)
Figure 2.2: Ecology Richness and Diversity of Microbiome
a) Microbiome richness plot of saliva sample and stool sample. (* P<0.05, **P<0.01)
b) Microbiome Shannon diversity and inverse Simpson index plot of saliva sample and stool sample. 
(* P<0.05, **P<0.01) 
c) Renyi Diversity of Microbiome in different age group. X axis represents the alpha value (increased 
alpha value means a higher weight on dominate organisms when calculating diversity), Y axis is 
the renyi diversity index calculated based on each alpha value. (* P<0.05, **P<0.01)
d) Power estimation for microbiome richness/diversity calculation. X axis is the simulated effect size 
and Y axis is the power. Four panels represent the results under different significance value, 
significance values are labeled on the top of each panel.
c) d)
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Bacteria taxonomic signatures in young and old subjects 
Although hierarchical clustering and PCA did not identify data from two age cohorts into distinct clusters, 
there is an evidence from ecological diversity calculations that some of the taxon may show a different 
abundant distribution between two age groups. To present those taxa that are different between two age 
groups, we performed a linear discriminant analysis based on effect size (LEfSe). 86 At significance level 
of 0.05 for factorial Kruskal-Wallis test, we identified 29 OTUs that are statistically more abundant in 
young cohort and 2 OTUs in old group within saliva sample. Also, the order of Bacteroidales, the class of 
Bacteroidia and the phylum of Bacteroidetes is more abundant in young cohort, and the family of 
Micrococcaceae is more abundant in aged group (Figure 2.3a). For stool samples, we identified 13 OTUs 
that are more abundant in young cohort, and 24 OTUs that are more abundant in aged group. Besides single 
OTUs, there are two clusters that are higher in aged populations. One cluster is the order of Coriobacteriales, 
and consequently the family of Coriobacteriaceae, the phylum of Actinobacteria and the class of 
Actinobacteria; another cluster is the family of Victivallaceae, order of Victivallales, class of Lentisphaeria 
and phylum of Lentisphaerae are more abundant in aged population (Figure 2.3a).   
 
The power for estimating OTU abundance comparison largely relies on the effect size, therefore the effect 
size is simulated here using the actual OTU relative abundance table (Figure 2.6a). We first calculated the 
standard derivation of OTUs by sample types and the host-age group (Figure 2.6a). Most SDs of OTU are 
below 2.5%, so SDs ranging from 1% to 5% are used to simulate the relationship between effect size and 
the sample-mean differences. From the simulation (Figure 2.6a), we can conclude that the effect size=2 is 
a large effect, which means we can detect a 4% relative abundance difference under the most cases 
(SD<=2%), those differences are likely to be biologically very meaningful. Effect size = 1 is a medium 
sized effect, which is good for generating hypothesis but hard to draw biological conclusions. Effect size 
that below 1 is a small effect which we may not have enough power to detect.  
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Figure 2.3: Taxa modulated by age
a) Age-related bacteria taxa calculated by LEfSE. Result is ordered with log-transformed Linear discriminant 
analysis score. Taxa with green bar are more abundant in young cohorts and with red bar are more abundant 
in older adults. Taxa are calculated from phylum level to single OTU. 
b) Random Forest result for using each OTU to predict age group. Random forest result plotted by “Mean 
Decreased Accuracy (MDA)”, which is calculated for each OTU that is the abundance distribution is randomly 
disrupted, how much of the accuracy will decrease when using this OTU to predict the age group of samples. 
For example, OTU_131 has a MDA larger than 200, it means if OTU_131’s distribution across samples is 
randomly changed, it will change the accuracy of using OTU_131 to determine which sample belongs to 
which age groups. Result was bootstrapped for 1000 times. 
b)
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After we performed an effect size simulation on our dataset, we next estimated the statistical power of 
comparing OTUs relative abundance based on the simulated effect size (Figure 2.6a). As I mentioned in 
introduction, the multiple comparison may introduce Type I Error, which undermines our confidence on 
the detected differential-abundant taxa between groups. Therefore, we may need to apply more stringent 
significance cutoff if performing too many comparisons. For instance, we identified around 500 OTUs in 
our data, which belong to 136 genera and 15 phyla. When we expect an OTU to be different from young 
and old groups, a p-value of 1e-05 would be a conserved cut-off, and our study power under this significance 
value is 0.16. If less comparison is involved by raising a defined null hypothesis (ie. compare taxa on higher 
taxonomy level, or only focuses on high abundant OTUs), we will have a better power. The power to detect 
large difference on phylum (15 comparisons, p=0.0033 before adjustment) and genus level (136 
comparisons, p=0.0004 before adjustment) are 0.96 and 0.74 respectively, to detect medium differences on 
phylum and genus are 0.31 and 0.09 respectively.  
 
Since LEfSe have a chance of missing OTUs that less prevalent, we employed another two methods for 
picking up taxonomies that show different distribution across groups. Random Forest (RF) 153 is a widely 
used method for classification and is one of the most accurate method for factor variables classification[ref]. 
154,88 It generates a variable importance score for each variable to indicate whether using the value of the 
variable would degrade prediction accuracy. We trimmed out OTUs with global variables less than 0.005 
in each site to remove less varied OTUs and obtained 258 OTUs in stool samples and 155 OTUs in saliva 
sample. Then we generated a list of 30 OTUs with highest importance value (Figure 2.3b).  
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a
b
Age-related Saliva Microbiome
Age-related Stool Microbiome
Not related
Old related
Young related 
c
Figure 2.4: Relative abundance of age related bacteria
a) Microbiome core reads percentage to total reads for each subject. Each column represents a subject. X axis 
shows the subject age. Gray part is the microbiome reads that do not linked to the two age groups. 
b) Venn Diagram comparing 3 methods. Upper left panel is Saliva Young microbiome that has been found by 3 
different method, numbers outside circles represent the number of OTUs generated by each method, upper 
area is the number for Random Forest, lower right is for Binary (prevalence) and lower left is for LEfSe. 
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If an OTU has a low relative abundance, but show distinct prevalence distribution between age groups, 
Random Forest may assign this OTU with low importance score since its importance estimation is based 
on the entire population. To compensate this, we also listed the OTUs that present in one age cohort but 
absent in another regardless of its abundance, and we named this type of OTUs as the “Binary” OTUs. 
Among all saliva samples, there are 103 binary OTUs in young population and 27 binary OTUs in aged 
population. Among stool samples, there are 24 binary OTUs in young population whereas there are 131 
binary OUTs in aged population (Table 1). A Venn Diagram summarizing the relationship of three methods 
is showed in Figure 2.4c. 
 
There is also statistical estimation on the detection power of “Binary” OTUs. For the presence-absence 
analysis, we cannot assume the probability of presence or absence of an OTU follows Gaussian. The 
presence-absence probability matrix is a classic example of binomial distribution. Thus, understanding the 
power of such comparison is based on binomial distribution.  
 
To estimate the study power for presence-absence analysis, the first parameter we need to determine is the 
background of presents (level of background noise). The background means how likely an OTU is artificial 
(not biologically real but being identified as an OTU by sequencing). During the data processing, we already 
accommodated the possibility that OTU is artificial by removing OTUs that have less than 5 reads (see 
method), so all remained OTUs are considered biologically present. Thus, the minimum valid detection for 
any given OTU is 1 out of 46 samples, and the detection limit (noise) was set to be 0.5 out of 46. 
Under this level of background noise, the study power to detect a difference on presence-absence is a simple 
function of how many cases of presence can be detected (Figure 2.6b). In our current design (red line), 
only the cases that one OTU is detected four times (40%) or more have a good detection power. Figure 2.7 
shows the taxa that are found more than four times, and this simulation provided the rationale for such 
selection.  
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Combining the three methods described above, we conclude that 155 OTUs from 381 OTUs in saliva 
samples, and 189 OTUs from 405 OTUs in stool samples are related to different ages (Table 1). The reads 
belong to those OTUs only occupy approximately 10% of relative abundance in saliva samples and 30% of 
that the stool samples, although it is about half of the number of OTUs. If we merge all age-related OTUs 
together, the relative abundance of this merged bacteria cluster is similar across samples from the same age 
group (Figure 2.4a, b). Among 155 age-related OTUs in saliva, 120 are more abundant or only present in 
young cohorts, 35 in old (Table 1). Among the young cohort related microbiome across 23 saliva samples 
(Figure 2.5a), 43.06% of the reads belongs to genus Prevotella, followed by Unclassified Prevotellaceae 
(12.89%) and Capnocytophaga (7.53%). For advanced age related OTUs in saliva samples (Figure 2.5b), 
Rothia occupies 81.15% of entire advanced age-related population, followed by Capnocytophaga (10.21%) 
and Prevotella (3.37%).  
 
In stool samples, 39 OTUs are more abundant or only present in young cohorts and 150 OTUs are in old 
cohorts (Figure 2.5c and Figure 2.5d). Among young cohort associated gut microbiome (Figure 2.5c), 
85.12% belongs to Bacteroides. This is consistent with several previous reports. 155-158 With 10 most 
dominant genus of young cohort related stool microbiome, half of them belongs to order Clostridiales, 
indicating that the order Clostridiales may be sharply affected by age. Among 53 genera found more 
abundant in aged cohort (Figure 2.5d), Lachnospiraceae Incertae Sedis and Unclassified Lachnospiraceae 
contribute to 26.26% of the entire population. 6.7% belongs to Bacteroides, 5.87% of this core population 
is Alistipes. This genus has been reported more abundant in aged mouse gut, 159 as well as associated with 
more frail aging population in Europe. 160 It is worth noticing that there are many unclassified bacteria 
OTUs in advanced-age related gut microbiome. Among those 150 OTUs, 7.23 % are unclassified 
Ruminococcaceae (0.56% in young cohorts), 2.24% are unclassified Clostridiales (0.35% in young cohorts), 
3.5% are unclassified Bacteria, and 2.86% are unclassified Prevotellaceae. 
39 
  
Saliva Stool Total number
Total OTU number 381 405 548
Total Reads Count 331977 267234 599211
Young Old Young Old
Age Associated OTU 120 35 39 150
Age Associated Reads 20038 21189 60876 26232
Binary OTU 103 27 24 131
Binary Reads 3105 219 1657 11866
Lefse 29 2 13 24
Lefse Reads 16331 16627 60262 10584
Random Forest 23 7 12 18
RF Reads 7513 5120 7926 8806
Table 1. OTUs identified by different methods
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Finally, we also want to get a general overlook on the age-related bacteria species that we have more 
confidences. Based on our power estimation, we removed the age-related OTUs that are less prevalent (40%) 
in one cohort and show an obvious distribution that associated with aging (Figure 2.7). Among those OTUs, 
OTU_197 (Figure 2.7) Tannerella was more prevalent and abundant in aged saliva sample than in young 
saliva sample. Given the fact that Tannerella forsythia and Treponema denticola are among 3 major 
pathogens that involved in periodontitis, 161 this could serve as a hint that oral cavity environment is 
friendlier to Tannerella growth in old individuals. Moreover, OTU_190 (Figure 2.7) belongs to a species 
of Prevotella. This OTU could only be found in young saliva cohorts and only present 164 reads in the 
entire sequencing. The same pattern was found in stool sample for OTU_447 (Figure 2.7). The loss of 
those Prevotella species may not affect the whole Prevotella population in terms of overall relative 
abundance, but it is very interesting to us that why a specific species (OTU) could appear or disappear 
during aging process. 
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a) Saliva microbiome related to young subjects b) Saliva microbiome related to old subjects
c) Stool microbiome related to young subjects d) Stool microbiome related to old subjects
Figure 2.5: Age related microbiome
a) Saliva microbiome related to young subjects contain 120 OTUs that belongs to 56 genera, the most abundant 15 
genera was listed here, and the other 41 genera are combined and plotted by “Others”. 
b) Saliva microbiome related to old subjects contain 35 OTUs that belongs to 24 genera, the most abundant 10 genera 
was listed here, and the other 14 genera are combined and plotted by “Others”. 
c) Stool microbiome related to young subjects contain 39 OTUs that belongs to 53 genera, the most abundant 10 genera 
was listed here, and the other 28 genera are combined and plotted by “Others”. 
d) Stool microbiome related to old subjects contain 150 OTUs that belongs to 53 genera, the most abundant 15 genera 
was listed here, and the other 38 genera are combined and plotted by “Others”. 
The percentage abundance is calculated by dividing the reads of each OTU to the total reads of this sample. A combined 
percentage plot is showed with circle plot which is a sum of the percentage abundance of each genus from all 23 subjects. 
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a
b
Figure 2.6: power estimation forage-related OTUs 
comparison
a) Effect and power simulation for t test based OTU 
comparison. Upper left panel shows standard 
derivation (SD) of OTUs by sample types and the 
host-age group. Upper right panel shows effect 
size simulation based on different SD (from 1% to 
5%) and differences between sample-mean(from 0 
to 5%). Three lower panels show power estimation 
based on different sample size and effect size. 
Expected significance values are labeled on top of 
each panel.
b) Power estimation for OTU presence/absence 
analysis. X axis shows the percentage of presence 
for any given OTU, Y axis shows the power to 
detect a difference between presence and absence. 
Color indicate how many samples are included in 
each group.
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Figure 2.7: Representative OTUs with more than 40% prevalence
The relative abundance of age-related OTUs that are more than 40% prevalence. Each dot represents one 
subject, with x axis shows this subject’s age and Y axis shows the percentage of read that belongs this OTU in 
each sample. Total reads across sample and subject was listed. Title shows phylum, class, order, family, genus 
and OTU number, “Unclassified” means this OTU could only be classified at a higher taxonomy rank. 
Young subjects
Old subjects
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Discussion 
This chapter presented our pioneer study which investigated the variations of microbiome in healthy aging 
of individuals from both stool and saliva samples. In spite of this being a small pilot feasibility cross-
sectional study, we were able to identify some statistically significant differences of saliva and stool 
microbiome between aged healthy cohorts and young controls. However, the dominant taxa and the overall 
population (as tested by PERMANOVA) of microbiome in young and old subjects are not significantly 
different. One possible explanation for this observation is that the dominant microbiome species is relatively 
stable during the aging process, especially when the subject is relatively healthy. This is confirmed later in 
a larger survey regarding the same topic. 158 We also provided a detailed analysis on power estimation since 
our study serves as a pilot, hypothesis-generating effort. The statistical power estimation discussed in this 
chapter can be served as effect size and sample size estimation guidelines for future experimental design.  
 
In our study, the gut microbiome in the aged cohort shows a trend of higher ecological richness and diversity. 
The increased gut microbiome diversity has been linked to aging in other studies as well. For example, 
higher richness of the bacterial microbiome has been observed in Drosophila melanogaster, 162 and an 
increased count of facultative anaerobes have been reported in antibiotics-free old subjects. 145 We think 
this increase in gut microbiome richness (or facultative anaerobes) of aged cohorts could be ascribed to a 
decline in the immune function in the gut. 163,164 For example, when hosts fail to provide inhibiting signals 
(such as anti-microbial peptides, specific and non-specific immune response) for bacteria growth, certain 
bacteria that are less sensitive to these inhibiting signals would start to colonize in the gut. Thus, the bacteria 
that colonize in older adults but cannot be detected in young subject may contribute to some age-related 
phenotypes. For instance, overgrowth of Clostridiales subpopulation in older adults is considered 
detrimental. 165 In our study, we found nine species belong to Clostridiales that are at least 40% abundant 
in gut microbiota of aged cohorts. 
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We next noticed the oral microbiome shows a lower richness and diversity in the older-adults group. there 
are several interpretations for this observation. First, this could be a result of different nutrition availability 
between oral and gut environment. The food digestion mainly occurs in gut, so that nutarians available in 
gut are richer than nutarians available in saliva. As a result, oral microbiome may response to aging 
differently compare to gut microbiome, both because of the bacteria species of the community are different 
and because the stability of the community is different. Second, it may because oral environment of older 
adults is a more difficult for bacteria colonize and growth than that of young. Phenotypes that are unfriendly 
to bacteria growth, such as tooth loss and Xerostomia (dry mouth), 166 are found more prevalent in old 
subjects.  
 
Based on our power simulation, the power to detect the difference of a richness/diversity between young 
and older adults is between 0.676 and 0.869. This indicates that our study is not underpowered for such 
comparisons. We also demonstrated that when a more stringent p-value is set, more samples are required 
to make the comparison. To achieve a high level of confidence on diversity differences (p-value < 0.01), at 
least 20 biological replicates with a p-value equal to 0.001 is required for each group of the study.  
 
In addition, we identified a highly abundant saliva OTU in gut microbiome of older adults, which may 
suggest a higher potential of microbial migration from saliva to gut in older adults. The concept of microbial 
migration has been proved and used as a signature of liver cirrhosis associated with microbiome dysbiosis. 
167 In our cohort, OTU_33 is identified as the second largest OTU of Streptococcus in saliva samples. The 
stool abundance of this OTU is significantly higher in old subjects, which indicate a possible oral 
microbiome migration in older adults. We think this observation may be an indication of general liver 
functional decline that associated with aging.  
 
Studies 168,169 on the human oral microbiome showed that patients with periodontitis had a low saliva 
bacteria ecological diversity due to the overgrowth of Selenomonas and Streptococcus. They proposed that 
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the imbalanced bacterial population may contribute to the inflammatory status of periodontitis. In our study, 
we also noticed one Selenomonas OTU (OTU_394) was more abundant in elder cohort than in young cohort 
(62% vs 20%, respectively). Similar pattern was observed for Tannerella (OTU_197), which was 
contributed to periodontitis. The higher abundance of those bacteria in older-adults cohorts may explain 
why older adults are more susceptible to periodontitis. 161,169 
 
However, we do notice a major limitation in this study, which is the small sample size and thus low 
statistical power. Although we do not have a good power (0.16) to detect OTU level differences for the 
current hypothesis, we do have a good statistical power to determine if we can reject the null hypothesis 
which is: the most abundant 20 OTUs between young and old subjects are the same in their mean relative 
abundance. Therefore, one of the conclusions in this chapter is that the dominant gut and saliva microbiome 
is relatively stable between young and old subjects. Based on our power estimation, we believe this 
conclusion is not underpowered and have biological significance. The ELDERMET project 160 and another 
project 143 also confirmed age is not a dominate contributor of gut microbiome inter-person variation among 
old. In fact, there were only 13 and 9 young-subject controls included in the study respectively, so that the 
detection power in two published studies is not very different from our study design. Remarkably, one of 
the well-designed studies, which included more than 1000 samples, directly confirmed our conclusion, that 
dominate gut microbiome is relatively stable, but subjects around 20-year-old show lower Shannon 
diversity because their Prevotella and Bacteroides are relatively more dominate. 158 
 
With our current study design, we have good detection power to distinguish whether bacteria presented 
more than 4 times are significantly different from bacteria that are never present. Also, our way of 
combining three methods together eliminates the problem of lowering detection power introduced by 
multiple testing. By merging those OTUs together and adjusted for SD (5% increase), our power of 
detection rises from 0.16 to a value between 0.47 (to detect medium effect size) and 0.80 (to detect large 
effect size).  
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In conclusion, we provided an overview of microbiome composition data in 23 human subjects in this 
chapter. By collectively using three statistical methods for comparison, we identified difference in richness 
and diversity between young and older adults’ microbiome. We also confirmed that the dominant organisms 
are relatively stable between two age groups. Therefore, the difference on richness and diversity is due to 
changes of less abundant organism. Also, we identified a salivary bacterial OTU which was more abundant 
in older adults’ gut microbiome. This observation exhibits signs of microbiome migration associated with 
aging. As a pilot project, this study not only showed power estimation for each step, but also offered a good 
size estimation for a study design aiming to understand difference in microbiome composition between two 
populations. 
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Chapter 3 
Background  
In the previous chapter, we described a detailed comparative analysis of microbiome from young and older 
individuals. We showed that the dominant members of the microbiome (defined by the relative abundance 
of 20 most abundant bacteria OTUs) is relatively stable across the age-related groups. However, differences 
do exist in ecological richness (the number of bacteria can be identified) and the ecological diversity of 
microbiome between young and older adults. Our analysis showed that bacteria with low relative abundance 
are contributing to the variations in ecological richness and diversity across the age-related groups. As a 
pilot study, the previous chapter also provided an example of statistical power and sample size estimation 
for future studies with similar experimental designs. In this chapter, we will extend our investigation of the 
microbiome plasticity to the study involving hosts with early stage type 2 diabetes (T2D). The overall 
hypothesis is: The interactions between microbiome and immune system are linked to the onset and 
progression of prediabetes.  
 
A dysregulation of microbiome, or microbiome dysbiosis, is commonly found in patients with type 2 
diabetes 170,171. A pioneer study comparing 18 diabetic males with 18 healthy males demonstrated that 
phylum Firmicutes and class Clostridia were reduced in diabetic individuals. 172 A larger study in European 
revealed a decrease in relative abundance of five Clostridium species and an increase of Lactobacillus in 
gut microbiome of T2D patients, 173 which is very similar to the result of a study in Japan. 174 Furthermore, 
Qin and his colleagues established a correlational association between the loss of certain clostridia 
population in T2D patients and a reduced SCFA production. 171 Later study confirmed this observation, and 
demonstrated that supplementary of SCFA-producing bacteria strains to T2D patients would improve their 
post-treatment clinical outcomes. 175 Meanwhile, the loss of microbial ecological diversity, another 
signature of the gut microbiome dysbiosis, 176 has been associated with obesity, 12 and T2D. 171,172 These 
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evidences collectively pointed out the possibility that dysbiosis might be associated with T2D onset and 
progression. Furthermore, transferring the gut microbiome from lean individuals to patients with metabolic 
syndrome can increase the insulin sensitivity of the recipients. Among 16 bacteria strains that increased in 
gut microbiome of recipients post procedure, 12 strains belong to the class of Clostridia. 177 
 
Given that type 2 diabetes are associated with inflammation 178,179 and signs of bacteria infiltration to host 
peripheral blood 180,181, we believe that the immune system regulating the gut microbiome may be involved 
in the development of T2D. Th17 cells are a subset of CD4 T helper cell that can be induced by combination 
of IL-6, IL-1β, and TNF-α. 179 This type of immune cells is closely related to the host regulation of gut 
microbiome through the secretion of anti-microbial peptides and the maintenance of gut epithelial barrier 
functions, 179 the disruption of which is a direct cause of bacteria infiltration. 182 Thus, Th17 cells are 
involved in maintaining the homeostasis between host and the gut microbiome. Dysfunction of Th17 has 
been reported correlating with gut microbiome dysbiosis in patients with multiple sclerosis, 183 IBD, 184 and 
systemic lupus erythematosus. 185,186 IL-17 and IL-22 are two type of cytokines that preferentially produced 
by Th17 cells187,188. Although the functions of IL-17 and IL-22 are not quite clear yet, it is generally believed 
that the two cytokines play a role in antimicrobial activities. 189-193 Reciprocally, signals from the gut 
microbiome could also affect Th17 cells activities in hosts. Germ-free mice do not carry Th17 cells in the 
gut, 92 but the inoculation of certain bacteria to germ-free mice can induce the development of Th17 cells. 
92,194 Interestingly, Atarashi and his colleagues demonstrated that the bacteria can induce Th17 cells are 
mainly from clostridium cluster XIVa, XIVb, XVIII, IV, and the class of Bacteroidia, Actinobacteria. Also, 
the authors claimed that the attachment of bacteria cell to gut epithelium was very important to the induction 
of Th17 cells in mouse model. 195,196 
 
The interaction between Th17 cells and the microbiome plays an important role in the onset of T2D in 
mouse models. TLR5 signaling is critical in the production of IL17 and IL22, 197 and a report showed that 
TLR5 -/- mice, whom cannot detect the flagellin from the gut microbiome, developed metabolic syndrome 
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spontaneously. 94 Also, the IL-17 deficient mice showed worse body weight control post HFD induced 
obesity. 198 This indicates that immune system mediated bacteria host interaction is required for host energy 
homeostasis. Garidou and his colleague showed that high fat diet (HFD) induced metabolic disorder in mice 
was associated with a reduction of CD4+ IL17+ cells population in the small intestine lamina propria (SILP) 
199. One possible explanation, as indicated by later studies, is that the HDF induced gut microbiome 
dysbiosis reduced the microbiome-produced metabolites that were required for maintaining Th17 cells. 
200,201 Consistently, mice fed with HFD also decreased the expression of IL-22 in the intestines. 200,202 
Similarly, in human subjects, IL-22 level in serum has been found significantly lower in patients with 
impaired fasting glucose and T2D.  203 Another group demonstrated that the lack of IL-23 mediated Th17 
cells maintenance increased the prevalence of glucose intolerance and insulin resistance in mice. 204 Lastly, 
studies showed that both adaptive transfer of Th17 cells to gut 205and the supplement of IL-22 202 alleviated 
the insulin resistance and metabolic disorders in mice. 
 
In humans, the relationship between Th17 cells, their related cytokines and diabetes is less clear.  As 
mentioned above, one recent study found the serum level of IL-22 was negatively correlated with the onset 
of T2D in humans. 203 However, other studies also claimed that IL-1β and IL-22 were the key contributors 
of obesity mediated metabolic disorders. 206 In addition to IL-22, there are also debates over whether IL-17 
plays a role in obesity mediated metabolic disorders. It was found beneficial in some studies. One study 
concluded that the decreased serum level of IL-17 was associated with metabolic syndrome and T2D related 
nephropathic complications. 207,208 Another study showed that, comparing with healthy controls, IL-17 level 
was higher in diabetes patients without diabetic retinopathy (relatively early-stage of T2D) but was lower 
in diabetes patients with diabetic retinopathy (relatively late-stage of T2D). Also, the production of IL-17 
in PBMC upon phytohaemagglutinin and ionomycin stimulation was negatively correlated with patient 
T2D duration. 209 
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On the contrary, the level of IL-17 has been proposed to be an independent predictor of future development 
of Insulin resistance in a Finnish female cohort. 210 Also, Th17 cell isolated from human T2D patient show 
higher level of IL-17 production post T cell mitogens stimulation. 211 Furthermore, the number of Th17 cell 
has been found positively correlate with severity of both T2D disease 211 and T2D related complications. 
212,213 
 
Therefore, more studies are required to understand the link between Th17 cell, diabetes and microbiome. 
With the access to iHMP data, we hypothesize that: the reduction of Th17-related cytokines in serum is 
linked to gut microbiome dysbiosis, indicating the onset and progression of prediabetes in humans.  
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b) Input variables and clustering result based on the three-cluster assumption 
Figure 3.1. GMM model to group IL17 and IL22 into different gaussian distribution
a) The Bayesian information criterion (BIC) simulation for the potential group number (Number of
components). The highest three BIC indicate the most likely numbers of groups based on GMM.
b) Pairwise correlation of three cytokines mean value and SD. Color represents the assigned group
of each sample point(blue=inactive group, red=intermediate, green=active group)
a) Model selection based on Bayesian information criterion
Our selection
Number of clusters
Figure 3.1. GMM model to group IL17 and IL22 into different gaussian distribution
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Result 
Description of iHMP Cohort  
According to the protocol of the iHMP, 105 individuals at risk of developing T2D were followed for a 
period of 1-4 years. During the study period, detailed multi-omics profiling was carried out four times per 
year, and more frequently during periods of self-reported stress, or upper respiratory infection [Ref main 
manuscript]. In this chapter, we used the repeated sampling of subjects as a basis for an analysis in which 
each subject was assumed to represent a fixed state relating to development of T2D. 
 
Within-individual cytokine variability identifies discrete groups of Th17 activity among iHMP 
subjects 
First, we hypothesize that the onset of metabolic disease is associated with altered Th17 cell cytokines 
production. To test this hypothesis, we tried to separate individuals based on their IL-17A, IL-17F, and 
IL-22 cytokines levels in the serum. This is based on the previous observation that serum IL-17 and IL-22 
level can be used as indicator of Th17 cell activity in hosts with rheumatoid arthritis, 214,215 Psoriasis, 216 
Takayasu Arteritis217 or  Crohn's disease. 218,219 We clustered individuals based on their serum-cytokine 
levels by Gaussian mixture modelling (GMM). GMM is a modeling method designed to identify the 
possible numbers of gaussian distributions in a given dataset. In our analysis, we used GMM to identify 
how many gaussian distributions can be found in iHMP participants based on their IL-17A, IL-17F and 
IL-22. We supplied the mean cytokine abundances and variance estimations over time for each subject to 
the model, which then indicated that the participants could be optimally separated into at least 3 groups 
based on Bayesian information criterion (BIC) (Figure 3.1a). Differences between the three groups are 
illustrated in a pairwise correlation plot (Figure 3.2b). Individuals at one gaussian distribution, 
characterized by consistently low cytokine mean abundances and variances (Blue Dots), can be separated 
from subjects at the other distribution, by high mean abundances and/or variances for one or more 
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cytokines (Fig. 3.2b). Based on the result from GMM, we concluded that longitudinally-sampled serum 
cytokine levels can distinguish discrete groups of subjects, with differences in cytokines that may reflect 
Th17 cell activities. We hence referred to the groups as ‘High Activity’ (HA), ‘Indeterminate Activity” 
(IA), and ‘Low Activity’ (LA) (Fig. 3.2a, b), to represent their inferred levels of Th17 activity. 
Importantly, we noticed that inter-individual variation does not overwrite the intra-individual variation 
(Figure 3.3a, b). This result lead us to speculate that identifying subject-clusters in this manner required 
estimating both inter- and intra-individual variation, which is not possible in cross-sectional data and 
hence necessitated a longitudinal study design.  
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Figure 3.2. Participants grouped according to IL-17/IL-22 cytokines
Figure 3.2. Grouping of iHMP participants based on Th17 related cytokine abundance
a) Gaussian Mixture Modelling of cytokine mean abundance and variance (see Online Methods) separates study
participants into three discrete groups (columns). Lines within each panel represent repeated measurements of
serum cytokine abundance for one individual over the study period. Rows represent serum cytokines associated
with Th17 activity (IL-17A, IL-17F, IL-22). CHEX4 is a measurement of background fluorescent intensity, and can
be treated as an negative control. (Note different scales on Y axis for each row).
b) Density distributions show the abundance of each cytokine within each group. Dashed lines represent the lower
limits of detection (LLOD) for the Luminex assay used to calculate cytokine abundance (see Methods). LLODs
are calculated as 3 standard deviations above the mean absorbance for the negative control associated with
each measurement. They can be interpreted as conservative thresholds below which the accuracy of
measurements may become limited. (IL17A: 64.4; IL17F: 140.5, IL22: 199.9)
a b
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In fact, the cross-sectional design of similar experiment will generate cases that one measurement is not 
enough to detect the possible existence of certain cytokines. We demonstrated this using an example 
(Figure 3.3c). We first took one random sample from each individual and generated a simulated cross-
sectional design of the same experiment. By comparing the IL-22 value from this simulated cross-
sectional experiment with the mean value of IL-22 from longitudinal design, we can identify 13 
individuals whose IL-22 measurements are under the lower limit of detection in randomly-subset samples 
but are above the lower limit of detection in mean value from repeated measures. Therefore, we believe 
that the cross-sectional design will generate a great amount of false positive signals in “LA” group, 
because we showed that one measurement is not enough to capture their real signal related to IL-22. This 
simulation justified our advantage of using longitudinal measurements from iHMP study. 
 
Also, mean values from repeated measurements will better fit the GMM because the distribution of the 
sample means will approach normally distributed when the sample size increases according to the central 
limit theorem. There is no clear definition on how many samples are required in central limit theorem. To 
get a relatively normal distribution without dropping too much samples, we excluded individuals who had 
been sampled less than 5 times from our analysis.  
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Figure 3.3  Comparison of the longitudinal design with the cross-sectional design 
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Figure3.3 Comparison of the longitudinal design with the cross-sectional design
Non-metric multidimensional scaling (nMDS) plots of study participants based on
a) microbiome compositions and b) cytokine profiles.
Repeated measurements from different individuals are colored separately to
highlight the relationship between intra- and inter-individual variation.
c) Compare the longitudinal design with the cross-sectional design for
measurements of IL-22. One random sample from each participant was taken in
order to simulate a dataset for cross-sectional study design, the blue box cover
samples that will be under the lower limit of detection for cross-sectional design,
but above the lower limit of detection under longitudinal design.
c
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Th17 HA individuals display milder metabolic syndrome related phenotype 
After we demonstrated that individuals may be assigned to three discrete groups, we reasoned that 
discrete Th17 cytokine profiles in three groups may reflect different stages of metabolic disorders 
progression. Previous studies in mice have demonstrated that loss of Th17 cells is an outcome of high fat 
diet induced metabolic syndrome. 199 While studies in humans have shown a negative correlation between 
serum level of IL-22 and the phenotypes of T2D. 203 Based on the results from these studies, we 
hypothesized that subjects with a Th17 LA profile would show more severe T2D-related phenotypes than 
subjects with a Th17 HA profile.  
 
To test this hypothesis, we firstly compared the insulin sensitivity among participants in different groups 
by using the steady state plasma glucose (SSPG) measurement which was available for two thirds (n=65) 
of study participants. Based on this measurement, individuals could be diagnosed as “insulin sensitive” or 
“insulin resistant”. We observed that SSPG levels were significantly higher in Th17 LA individuals 
compared to Th17 HA individuals (Wilcoxon test, W=64.5, p=0.021, Figure 3.4). As a result, Th17 LA 
individuals were more frequently insulin resistant (Figure 3.5a). Consistent with this result, we found 
three-month average glucose (A1C) level tends to be slightly higher in Th17 HA group, but not 
statistically significant (Figure 3.6). However, mean fasting plasma glucose (FPG) levels, age, and body 
mass index (BMI) did not vary significantly across groups (Figure 3.5b). 
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Figure 3.4 Steady State Plasma Glucose (SSPG) measurement by group. 
P-values for pairwise Wilcoxon test are labelled above the bar plot, the  p-value for a 
one-way ANOVA test is labelled under the bar plot. 
LA: Th17 Low-Activity group, 
IA: Th17 Indeterminate-Activity group, 
HA: Th17 High-Activity group
Figure 3.4 Steady State Plasma Glucose measurements by group
m
g/
dl
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Secondly, we modelled longitudinal clinical data collected across the 4-year study period to investigate 
the metabolic profiles difference between groups. Using the linear mixed model, we looked for multiple 
markers that may suggest differences between Th17 LA subjects compared to Th17 HA or indeterminate 
subjects. Interestingly, Th17 LA individuals showed significantly lower plasma high-density 
lipopolysaccharide (HDL, Figure 3.6) and higher plasma triglycerides (TGL, Figure 3.6). Both a 
decrease of HDL and an increase of TGL has been observed in T2D patients, indicating our LA group has 
higher risk for T2D development. 220 Additionally, serum sodium and chloride levels were higher in the 
Th17 LA group (Figure 3.6). From previous studies, we know that high insulin might be associated with 
increased sodium retention in T2D patients, 221 so this result is also in line with our hypothesis that Th17 
LA group showed higher risk for T2D.  
 
Finally, we examined a red blood cell volume measurement among our participants. The rationale for this 
analysis comes from a previous large-scale study which identified low red blood cell distribution width 
(RDW) as being associated with low HDL and high TGL, and thus negatively correlated with risk for 
T2D. 222 As we expected, the RDW was significantly lower in Th17 LA subjects among our iHMP 
participants. (Figure 3.6). 
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Figure 3.5. Age, BMI and glucose level of subject from different groups
Group 1: Th17 LA
Group 2: Th17 IA
Group 3: Th17 HA 
Group 
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Figure 3.5 Age, BMI and glucose level of subject from different groups
a) Percentage of insulin resistant individuals in each of the group. Total number of 
individuals are labelled on top of each column. IR: Insulin Resistant; IS: Insulin Sensitive
b) Comparison of age, Body Mass Index(BMI), and Fasting Plasmid Glucose (FPG, mmoL/L) 
across groups. Pairwise t test was performed(* P<0.05, ns: p>0.05)
Group 1: Th17 LA
Group 2: Th17 IA
Group 3: Th17 HA 
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Figure 3.6 Longitudinal modelling of serum
metabolism marker and blood cell volume marker
show higher type 2 diabetes risk in individuals from
LA group
X3 represents the Th17 HA group, X2 presents IA group, the
group is treated as categorical variables (see Online Method).
Sex, age (adjusted for the length of their study involvement),
BMI and length between project start to each sample collection
(Days) are included in building the model. Regression
coefficient (beta) is plotted for each variables. Thick lines for
each variable indicate 50% Credible intervals or ± 1 SD, thin
lines for 95% CI or ± 2SD.
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In conclusion, analysis on multiple biomarkers of metabolic disease progression indicated that Th17 LA 
subjects display a more severe clinical phenotype than Th17 HA subjects, supporting our hypothesis that 
loss of Th17 activity may be associated with the onset and progression of T2D.  
 
Th17 HA individuals have a gut microbiome characterized by a high level of Clostridia 
Based on the close association between Th17 cells and the gut microbiome, 92,223 we next asked whether 
subjects distinguished by Th17 cytokine profiles differed in the composition of their gut microbiome. As 
a subject’s gut microbiome remained relatively stable throughout the course of this study (Figure 3.3), 224 
we began by comparing mean microbiome abundance values for each subject between Th17 LA and 
Th17 HA groups. Th17 LA subjects had a significantly lower alpha diversity compared to Th17 HA 
subjects (Wilcoxon test, W=34.0, p=0.003, Figure 3.7)) and a lower Firmicutes: Bacteroidetes (F/B) ratio 
(Wilcoxon test, W=54.0 p=0.044, Figure 3.7). Furthermore, in order to take the repeated measurement 
design into our comparison, we performed LMM to address the same question. The results from LMM 
were consistent with our comparisons made on mean values (Figure 3.8, 3.9). Multiple studies also 
demonstrated a functional association between members of the Firmicutes (taxa associated with the class 
Clostridia) and Th17 cell proliferation. 196,225 Our results therefore indicate that the gut microbiome of 
Th17 HA individuals is enriched in microbial taxa known to influence Th17 cell abundance. 
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Figure 3.7 Differences in the gut microbiome of HA vs LA individuals
a) Shannon diversity estimates for the HA group and LA groups. Mean value of diversity
for each participant across the study period is used to generate this plot. The p-value
from a Wilcoxon test is labelled above the plot.
b) Firmicutes to Bacteroidetes ratio of HA group and LA groups. Mean value of F/B ratio
for each participant across the study period is used to generate this plot. The p-value
from a Wilcoxon test is labelled above the plot.
c) Cladogram representing the LEfSe results for comparing taxa abundance between HA
and LA groups. Circles on the cladogram represent the phylogenetic relationship of
taxa that are tested, with phylum at the center and OTU on the edges. Each point
represents a taxonomic unit. Red color covering a dot/region indicates the taxa that
are more abundant in the HA group, blue color covering a dot/area indicates the taxa
are more abundant in the LA group.
Figure 3.7 Differences in the gut microbiome of HA and LA individuals
a b c
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To further investigate the relationship between Th17-related cytokines and the gut microbiome, we used 
data from Th17 HA and Th17 LA individuals to perform longitudinal modelling of the pairwise 
relationships between individual bacterial genera and cytokine abundances. Previous studies have 
identified significant associations between cytokines and the gut microbiome, but their cross-sectional 
design means they have focused on inter-individual variation. 121 By using the repeated measurements for 
each individual in the iHMP study, we addressed the possibility that intra-individual variation in 
cytokine/bacteria abundance may be used to identify host-microbe associations of biological interests. We 
used a mixed-effects model with random effects introduced by repeated measures to accommodate 
within-subject correlation. To accommodate the zero-inflated nature of microbiome abundance counts we 
used a Bayesian framework with a negative binomial distribution with a sparse matrix. Th17 groups (HA 
vs. IA) and cytokines (either IL-17A or IL-17F) were included as fixed effects, as was an interaction term 
for the combined effect of Th17 group and cytokine on microbe abundances. We excluded IL-22 
excluded from this analysis because a large proportion of IL-22 measurements appeared to be below the 
sensitivity threshold of the Luminex assay (Figure 3.2) and were not reliable for longitudinal modelling. 
We included the Th17 cell related cytokine interaction-term with the specific aim of testing the 
hypothesis that significant microbe-cytokine associations may be detected in Th17 HA individuals that 
are not present in Th17 LA individuals.  
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Figure 3.8. Longitudinal modelling of Shannon diversity show higher diversity in HA group
Th17 HA group
Th17 IA group
Figure 3.8. Longitudinal modelling of Shannon diversity show higher diversity in HA group
The sex, age and BMI is included to build a model for the relationship between Th17 related 
groups and their gut microbiome Shannon diversity. Regression estimates are plotted with 
thick lines for each variable indicate 50% Credible intervals or ± 1 SD of the correlation 
coefficient, thin lines for 95% CI or ± 2SD.
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Longitudinal modelling of microbe cytokine interactions indicated that the abundance of genus Alistipes 
varied significantly in response to changes in IL-17F level in serum (Figure 3.10). As models were 
designed to compare cytokine vs. microbe interactions in the context of Th17 activity (encoded as HA vs. 
IA), this result indicates this genus was significantly associated with IL-17F in Th17 LA individuals. In 
contrast, seven bacterial taxa were significant for the Th17 group: cytokine interaction term (Figure 
3.10), indicating their abundance was significantly associated with IL-17F or IL-17A cytokine level in 
Th17 HA individuals only. Notably, 6 out of 8 of these significant relationships involved taxa belonging 
to the class Clostridia, and in all 8 cases, cytokine abundance was positively correlated with taxon 
abundance (Figure 3.10).  In conclusion, analysis of variation in the taxonomic abundance of gut 
microbiota between individuals (Figure 3.2) and within individuals (Table 1) both provide evidence that 
members of the class Clostridia are associated with increased levels of Th17 cell activity. 
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Figure 3.9. LMM model to compare Firmicutes/Bacteroidetes ratio
Th17 HA group
Figure 3.9. Longitudinal modelling of Firmicutes to Bacteroidetes ratio show higher ratio in
HA group
The sex, age and BMI is included to build a model for the relationship between Th17 related
groups and Firmicutes to Bacteroidetes ratio. Regression estimates are plotted with thick
lines for each variable indicate 50% Credible intervals or ± 1 SD of the correlation coefficient,
thin lines for 95% CI or ± 2SD.
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Correlation in LA Group Correlations in HA Group
Figure3.10 The Genera Correlate with Serum IL-17
Figure3.10 The Genera Correlate with Serum IL-17
Significant correlations between serum IL-17 and bacterial genus abundance are shown 
for Th17 HA individuals (red panels) and Th17 LA individuals (blue panel). 
Distributions show estimated effect sizes from Bayesian Markov chain Monte Carlo 
draws after parameter convergence. Panels show bacteria for which the estimated 
effect is significantly greater or less than 0 (95% credible interval does not include 0).
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Discussion 
This analysis of the iHMP prediabetes dataset provides an opportunity for detailed exploration of human-
microbiome associations which is hard to achieve in the smaller, cross-sectional studies. The longitudinal 
design of iHMP allowed us to access the chronic properties of human Th17 related cytokines, and thus to 
distinguish individuals who have either high absolute value of cytokine or high variation of cytokine from 
individuals who have very low cytokine production across years.  
 
Based on our analysis, we propose that human subjects with a Th17 LA profile and loss of Th17-cell-
inducing bacteria in the gut display higher potential risk for metabolic disorders based on several clinical 
markers. This observation has been made in mouse models previously yet have not been detected in 
humans. Our observation that, longitudinal monitoring the individuals might be necessary to this 
discovery, may explain why it is not shown until today.  
 
Our results strengthen support for the hypothesis that gut microbial dysbiosis previously described in T2D 
patients may arise due to malfunction of host Th17-related regulation of the gut microbiome. 
Reciprocally, altered gut microbiome composition may further reduce signals that stimulate Th17 cell 
differentiation and maintenance. As both Th17 cells and their related cytokines are a critical component 
of a healthy intestinal epithelial barrier, 204,218 there might be causational effect beyond the observed 
correlations. For example, Aryl hydrocarbon Receptor (AhR) signaling is critical for maintenance of 
Th17 cells, 226 and is reduced after mice are switched to a high fat diet. 200 The decrease of Th17 cell 
related cytokines may trigger the vicious circle of gut barrier malfunction and gut microbiome dysbiosis.  
 
However, there was several limitations that we need to discuss. First, in the current dataset, we do not 
have the measurements on short chain fatty acid (SCFA) level in stool samples, thus could not address the 
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possible effects of SCFA on either Th17 cells or metabolic profiles. The hypothesis that SCFA may 
induce Th17 cell proliferation are currently investigated by other groups. 227 
 
Second, we do notice the complication of diabetes among individuals. Although we can establish 
correlation between microbiome, Th17 related cytokines and measurements such as HDL, LDL or 
glucose, we must point out that diabetes is a complicated syndrome that beyond one measurement. For 
example, one of our participants (Randomized ID: ZVNCGHM) who was clinically diagnosed as 
“Diabetes” based on his FPG level (138 mg/dL), was clinically categorized as “insulin sensitive” based on 
his SSPG (67.13 mg/dL). Meanwhile, four participants who were categorized as “healthy control” based 
on their A1C levels are diagnosed as “insulin resistant” based on FPG. The two examples demonstrated 
cases when participants have normal insulin sensitivity, and when participants have normal glucose 
sensitivity but impaired insulin sensitivity. This complication of diabetes limited our ability to correlate 
our result simply with different stages of diabetes progression.  
 
In conclusion, this chapter demonstrated a correlational relationship between human gut microbiome and 
T2D progression. It provides a new perspective in which certain bacteria in gut microbiome could affect 
human metabolic process through interacting with the host immune system, raising the possibility that 
therapeutic targets, related to Th17 cells, may effectively alleviate metabolic diseases in human subjects 
as they do in animal models.  
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Chapter 04  
Conclusions and Future Direction 
In summary, the studies in this thesis demonstrated the plasticity of microbiome under the influence of 
healthy aging and prediabetes. Also, it established a new link between human gut microbiome dysbiosis 
and the progression of metabolic diseases. Notably, the proposed association we found between microbiome 
and immune system effectively validated numbers of observations in mouse model and provided a new 
possible etiology of human T2D onset and progression. 
 
In line with several previous studies, 19,158 we did not identify dysbiosis in healthy aging individuals with 
our current study design. In theory, the previous studies and ours might miss the taxonomy abundances 
differences which have smaller effect size. However, the consistent results between our project and other 
studies strengthened our confidence that we observed a biologically-valid phenotype: In healthy individuals, 
the microbiome identities are to some extent stable, and we speculate that even if there are nuance 
taxonomical differences between young and aged cohorts, they might not be dramatic enough to influence 
the host health status. On the other hand, if we think this observation in a survivorship bias prospective, it 
might indicate that individuals who have dramatic microbiome changes may unlikely be healthy. In fact, 
there are links between frailty in older adults and dramatic gut microbiome changes, 155,228 which indicates 
that dysbiosis may correlate with age-related disease phenotypes instead of chronological ages alone.  
 
However, we cannot definitively reject the hypothesis that microbiome in old individuals might be in higher 
potential to switch to dysbiosis, especially when considering that old individuals often have chronic low-
grade inflammation and immunosenescence. We did a small-scale study regarding this hypothesis in mice. 
To test if aged mice are more likely to develop dysbiosis during inflammation, we proposed an experiment 
described in the Appendix. Briefly, we compared the microbiome plasticity in young (5–6 months old) and 
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old (19–21 months old) post influenza viral infection. We already know from a previous publication that 
A/PR/8/34 (PR8) strain of influenza virus does not infect gut tissue229, thus we believe the microbiome 
plasticity we observed post-infection is a response to mucosal inflammation mediated by IFN 230 and Th17 
cells. 229 In response to infection-induced inflammation, the gut microbiome of aged mice changed the same 
way as it is in young mice in day 4 and day 7. Therefore, we concluded that the microbiome plasticity in 
aged mice do not change in response to such flu-induced inflammation, and such changes in humans 
remained unclear. 
 
Although we did not identify any dramatic age-related dysbiosis in our human aging microbiome study 
(chapter 2) and the study described in mice, a study from McMaster University do show that transferring 
the gut microbiome from aged mice to young recipient mice may induce an increase of TNF-a and IL-6 in 
those recipient mice. 231 When carefully comparing their animal cohorts with ours, we found two major 
differences: 1) the mice at McMaster University (MC) and UConn Health Center (UCHC) do not bare the 
same gut microbiome. The microbiome in mice from MC shows high abundance of genus from Escherichia, 
Alistipes and Klebsiella, which cannot be found in the most 10 abundant genera in microbiome from UCHC 
mice (Figure 4.1); 2) the mice at MC show an age-related increase in TNF-alpha and IL-6 in plasma and 
lung tissues at the baseline level (before fecal microbiome transplantation (FMT)), whereas the mice at 
UCHC do not have such phenotypes. So, the correlation between age and increased pro-inflammatory 
cytokines may be specific to the MC cohort. In addition, the FMT experiment from a later study 232 also 
tried to claim that aged microbiome caused systemic inflammation. However, they observed that 
transferring the young microbiome to recipient mice induced an upregulation of TLR4 (an immuno-sensor 
for bacterial Lipopolysaccharides (LPS)) only when recipient mice are germ-free. As a result, current 
evidences are not convincing enough to establish causational relationship between microbiome dysbiosis 
and aging.  
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Figure 4.1 Comparison of the gut microbiome between 
Young and aged mice from UConn Health Center
Young old
Figure 4.1 Comparison of the gut microbiome between Young and aged mice at UCHC
Microbiome relative abundance from young (5–6 months old) and old (19–21 months old)
C57B6/J mice from UConn Health Center (UCHC), the ten most-abundant genera are
annotated by color (lower part of the right plot).
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Therefore, whether aged-microbiome causes inflammation also remains unclear, and more studies are 
required. One experiment that need to be done is to establish an association between certain bacteria genera 
(or even species/strains) to an increase in chronic low-grade inflammation instead of chronological age, and 
to design the FMT experiment using the bacteria isolates that are known to correlate with the increasing of 
cytokines levels such as TNF-a and IL-6 (which are the biomarkers of chronic low-grade 
inflammation233,234). However, one of the big challenges in such studies is to meet the sample size and study 
power requirements to get accurate estimates on potential correlations between bacteria and cytokines. 
Studies focus on “chronic” and “low grade” inflammation usually require a longitudinal sampling in order 
to identify cytokine differences in small effect size, which naturally lead to a very large sample size 
requirement.  
 
Lucky, the iHMP provided such an opportunity to study the relationship of systemic chronic inflammation 
and the early progression of an inflammation-related disease, prediabetes. 224,235 Unlike chronic low-grade 
inflammation which is characterized by elevated serum level of IL-6 and TNF-a, we hypothesized that 
prediabetes associated inflammation might be linked to plasticity of Th17 cell-related cytokines. The 
detailed rationale of such hypothesis was discussed in Chapter 3.  
 
One of the major conclusions we made from Chapter 3 was: the serum levels of IL-17 and IL-22 could be 
an indicator of prediabetes progression. There are contradictory results from previous studies about whether 
IL-17 increases as a result of T2D. On one hand, IL-17 and IL-22 has pro-inflammatory properties, 236,237 
an increase in IL-17 and IL-22 has been linked to many inflammation-related disorders; 236,238 On the other 
hand, IL-17 and IL-22 are required for gut epithelium function, thus have anti-inflammatory role, and a 
reduction of which could also lead to an inflammation caused by the “leaky gut”. 239,240 This controversy as 
well as the actual function of IL-17 and IL-22 has been previously reviewed. 189,241-243 We hence proposed 
a model which we think will explain our result, and potentially the results from previous studies. 
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This model is explicitly illustrated in Figure 4.2. We used four colors (green, red, grey and blue) to 
represent the stages of prediabetes progression reflected in this study. Green zone represents individuals in 
relatively low risk for T2D. The transit from green zone to red zone indicate the onset of inflammation, 
which correlates with an increased risk for T2D. In the cohort described in Chapter 3, participants in “HA” 
group are likely in this stage, whose serum contains high levels of IL-17 and IL-22. The previously reported 
244 positive correlations between obesity and level of IL-17 may be observations of individuals in this stage. 
If the inflammation persists, multiple immune pathways will be activated, which may influence members 
of the gut microbiome which are susceptible to inflammation. In line with this theory, we observed a 
reduced bacteria diversity after flu induced systemic inflammation in mice. 245 The fact that we can observe 
this decreased diversity at Day 4 post infection implied this is likely an innate inflammation, and therefore 
non-specific. This inflammation may be the cause of decreased microbiome ecological diversity. Data from 
studies in both our appendix and chapter 3 indicate that phylum Proteobacteria is more resistant to this 
inflammation induced decrease of diversity. The gut microbiome dysbiosis (characterized by decreased 
diversity of microbiome) may not only be a result of inflammation but also contribute to the inflammation 
in many ways. When the vicious circle of dysbiosis and inflammation developed into certain stage, it is 
possible that the adaptive immune system will be involved and response to all the bacteria genus that are 
detectable by antigen presenting cells. As a result, bacteria in a microbiome community that are detectable 
to the immune system will reduce, hence the interaction between the gut microbiome and the immune 
system will decrease.  
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• Increased risk for Type 2 Diabetes
• Increased chance of Insulin resistance (increased SSPG)
• Increased gut permeability (because the lack of Th17 cells related cytokines)
• Increased chance of obesity (increased BMI, increased low-grade inflammation)
• Increased Bacteroidia, decreased Firmicutes, Clostridia
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Figure 4.2 Hypothesized model for plasticity of Th17 relate cytokines 
and microbiome during prediabetes progression
Clostridia
Figure 4.2 Hypothesized model for Th17 relate cytokines and microbiome plasticity 
during prediabetes progression
The x axis indicate the early onset and progression of diabetes, from left to right, the risk 
for diabetes increases. Y axis indicate the level of Th17 cells, when transit from green 
zone to red zone, the Th17 cell related cytokines increase as a result of inflammation. 
From red zone to blue zone, the Th17 cell related cytokines decrease as a result of 
diabetes progressing. The Purple line indicate the hypothesized increase and decrease of 
Clostridia population. We think the Clostridia plasticity is one of the cause of the 
variation observed in Th17 cell related cytokines based on previous publications. 
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In our analysis, we believe that individuals from the “LA” group are under such a condition. Consistent 
with our speculation, we found less microbiome genera are correlated with the Th17 related cytokines in 
the “LA” group, and individuals in the “LA” group maintains a very low level of microbiome diversity, 
which indicate a gut microbiome dysbiosis phenotype. As a result, some signals from the gut microbiome, 
which are required for the maintenance of metabolism homeostasis, such as TLR5 mediated signals94  and 
the aryl hydrocarbon receptor mediated signals, 200,246 are likely absent or reduced. 
 
However, our analysis also has limitations. We will discuss two major ones. First, our result did not 
elucidate the origin of IL-17 and IL-22. Although the production of IL-17 and IL-22 has been generally 
linked to the activity of Th17 cells, we cannot exclude the possibility that other types of cell are also 
responsible for the observed IL-17 and IL-22 variations. In fact, several research groups demonstrated the 
IL-17 and IL-22 production from gamma delta T cells (γδ T cells) 247 and Mucosal Associated Invariant T 
(MAIT) 248 cells, and it is still unclear what proportion of IL-17 and IL-22 in serum is from these cell types. 
Also, the data from the Th17 “HA” group may have only one Th17 cell related cytokines showed a high 
level, but two others showed low levels. Thus, we could only interpret our “IA” and “HA” group as having 
low and high probability that their Th17 cells are active, but we cannot directly equal the cytokine level to 
their Th17 cell activity. Second, we lacked the measurements to correlate the Th17 cell related cytokine to 
the progression of diabetes due to the complication of this disease. We could only conclude that the “HA” 
and “LA” group may show different level of SSPG or similar level of FPG and using those correlation to 
interpret the prediabetes progression. However, when taking other measurements into consideration, we 
found our study design is not powered enough to identify an absolutely “healthy-control” group in which 
individuals have no risk for T2D. This situation is illustrated in figure 4.3. It is worth noticing that the two 
subjects who have highest FPG in this cohort are insulin sensitive. Also, as we mentioned in Chapter 03, 
several individuals who have normal glucose level (measured by A1C<5.7%) are insulin resistant. 
Therefore, instead of using discrete “sick” and “control” category to group individuals, we tend to think 
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that the cohort are all under risks for type 2 diabetes, and some participants (relatively healthier) have lower 
risk than the others. We believe that treating the diabetes risk as a continues variable is a better model of 
the disease progression, however the major limitation is that this risk cannot be mathematically quantified, 
therefore we cannot computationally correlate any measurement to the overall risk of diabetes.  
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Figure 4.3 Participants clinical category 
The clinical category of each individual is color labeled as the background of this scattered 
plot. Each dot represent a participant from iHMP2 project. Grey dot means the indicated 
individual do not have more than five repeated measurements, thus they do not have an 
assigned group from GMM. 
SSPG  > 150 mg/dL are categorized as insulin resistant [PMID: 17957034]
Among individuals whose SSPG < 150 mg/dL (which is considered insulin sensitive), FPG  < 
100 mg/dL is considered healthy, 100 < FPG < 150 mg/dL is considered prediabetic, FPG > 
150 mg/dL is considered diabetic. http://www.diabetes.org/diabetes-basics/diagnosis/
81 
 
Regarding the limitation we mentioned, there are several experiments that can be proposed at the end of 
this thesis. We are going to propose following experiments:  
 
1) To identify the age-related gut microbiome changes 
As mentioned in chapter 2, we propose to increase the sample size in order to detect smaller changes 
in the gut microbiome of older adults. Also, we believe that the chronological age might not be the 
most ideal measurements when searching for age-related gut microbiome compositional 
differences. Therefore, we would like to add two additional points in testing the hypothesis that: 
age-related microbiome changes are linked to the increased low-grade chronic inflammation. First, 
we propose to include at least 20 individuals in each group to achieve a reasonable power estimation, 
instead of 10 individuals in our previous study design. Also, in addition to young and old groups, 
we propose to include a frail group. The additional frail group would allow us to compare the age-
related microbiome difference under healthy and unhealthy conditions, and test if the microbiome 
dysbiosis is more prevalent in frail group. The result from this experiment will better test if the gut 
microbiome is relatively stable during the healthy aging. Second, we propose to measure the 
biological ages in addition to the chronological ages. It has been proposed that individuals could 
have different biological ages compared to their chronological ages. There are ways to measure 
biological ages such as measure the serum level of IL-6 and TNF-a. 249,250 The measurements 
regarding biological ages will allow us to establish associations between the gut microbiome 
plasticity with certain biological phenotypes such as low-grade chronic inflammation, therefore 
increase the biological relevance and significance of searching for age-related microbiome 
differences.  
 
2) To validate the correlation between gut microbiome and Th17 cells  
Fecal microbiome transplantation (FMT) experiments are widely used to establish causational 
relationship between the gut microbiome and the biological phenotypes. We propose the 
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application of such experiments to validate our finding about the correlation between class 
Clostridia and the activity of Th17 cells. Specifically, we could transplant the stool samples from 
individuals belonging to “HA” and “LA” group to germ free mice and measure the Th17 cells 
development and function in the recipient mice. If the results are the same as expected, we should 
observe more Th17 cells and/or Th17 cell related cytokines in mice which received the stool sample 
from “HA” group donor (high Clostridia) than “LA” group donor (low Clostridia). Meanwhile, we 
propose to measure the gut epithelium function and insulin sensitivity of the recipient mice. If our 
hypothesis is true, we should expect a better gut epithelium function and better insulin sensitivity 
in mice which received stool samples from “HA” group individuals. These FMT experiments will 
help us establish the causational relationship between the gut microbiome and the Th17 cells related 
cytokines.  
 
3) To validate the deterioration of Th17 cell functions under high glucose environment 
To further understand the Th17 cells activity under different glucose environment, we propose to 
culture PBMC/Th17 cells in different glucose concentrations. According to our result, there is a 
trend of increased A1C in “LA” group, indicating that a high glucose level may correlate with a 
decrease of IL-17 and IL-22 levels in serum. We therefore hypothesize that the chronic exposure 
to high concentration of glucose would induce an “exhaustion” like phenotype in Th17 cells. T cell 
exhaustion describes a deterioration of cell functions after T cells are exposed to chronic antigen 
or inflammatory signals. 251 T cell exhaustion is normally seen in cancer patients with persistent 
cancer antigens or in chronic viral infections 251-253. After treat the Th17 cells in high glucose 
condition, they show a proinflammatory phenotype by upregulate the IL-17 and IL-6 expression, 
indicating that high glucose environment may be considered as an inflammatory signal under 
certain circumstances. 254 Therefore, chronic exposure of the Th17 cells to the high glucose 
concentration may drive the Th17 cells to a phenotype that are similar to the T cell exhaustion. To 
validate this theory, we think culturing Th17 cells isolated from diabetes patients (and healthy 
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individuals) in different glucose conditions and measuring cytokine production as well as markers 
of T cell exhaustion will contribute to our understanding of the role Th17 cells plays in the onset 
and progression of T2D. 
 
4) To rescue the differentiation and function of Th17 cell by blocking the glycosylation 
According to a previous report, high fat diet induced metabolism is correlated with a decrease in 
number of Th17 cells in mouse model. 199 Similarly, in iHMP2 cohort, individuals in the Th17 “LA” 
group are those who have higher risks for T2D onset and progression. These results indicated that 
high level glucose may be detrimental for Th17 cells. We therefore hypothesize that reducing the 
glucose exposure of Th17 cells will enhance the differentiation and function of Th17 cells in T2D 
patients. To validate this hypothesis, we propose an experiment to reduce the glucose availability 
of Th17 cells and observe the functional changes post treatments. The Th17 cells and PBMCs of 
T2D patients can be collected and cultured under low glucose or no glucose condition or with the 
know inhibitory chemicals that block the metabolism of glucose, 255 and the IL-17 and IL-22 
productions in cell cultures can be measured and compared. Taking this experiment and the 
experiment proposed in the above paragraph, we will have a better understanding of how Th17 
cells behaves under different glucose conditions.  
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Appendix I: Methods 
Sample Collection 
Fecal samples were collected using Fisherbrand™ Commode Specimen Collection System (Thermo Fisher 
Scientific, Waltham, MA, USA). Saliva samples were collected by asking each participant to let saliva 
collect in the mouth for at least 1 minute. The participant was then asked to drool into the labeled 50 mL 
collection tube (Falcon, sterile conical polypropylene tube with flat-top screw cap). This process was 
repeated multiple times in order to collect 2-5 mL of saliva. The specimens were kept at cold until stored 
at -80 C or for DNA extraction.  
 
DNA Sequencing 
Fresh samples were stored at -80 ℃ immediately after collection. Total DNA was extracted from 
fecal/saliva samples using the Power Soil DNA Extraction kit (Mo Bio Laboratories, Carlsbad, CA, USA) 
according to manufacturer’s protocol. Bacterial 16S rRNA gene DNA was amplified using the 27F/534R 
primer set (27F 5′-AGAGTTTGATCCTGGCTCAG-3′, 534R 5′-ATTACCGCGGCTGCTGG-3′). PCR 
reactions were performed using phusion high-fidelity PCR Master mix (Invitrogen, Carlsbad, CA, USA) 
with the following condition: 95 °C for 2 min (1 cycle), 95 °C for 20 s /56 °C for 30s /72 °C for 1 min (30 
cycles). PCR products were barcoded and purified using Agencourt AMPure XP beads (Beckman coulter, 
Brea, CA, USA) according to manufacturer’s protocol. Libraries were prepared with Illumina’s protocol 
for MiSeq platform. DNA sequencing was conducted on an Illumina MiSeq system. The sample processing 
was complied with Human Microbiome Project standard protocol (#07-001. V12.0). 
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Sequencing Data Process for Chapter 2 
Raw reads were filtered according to sequence length and quality. Filter-pass reads were assembled using 
the Flash assembly software, for which the minimum overlap requirement is 30 bps, and the maximum 
mismatch ratio is 10%. 256 After assembly, chimeric sequences were removed using the USEARCH 
software based on the UCHIME algorithm. 257 After the barcode was removed from each sequence, 
Operational Taxonomic Units (OTUs) was calculated using a de novo OTU picking protocol with a 95% 
similarity threshold. Taxonomy assignment of OTUs was performed by comparing sequences to The 
Ribosomal Database Project (RDP) 258 at https://rdp.cme.msu.edu/ with a similarity cutoff of 0.8. 259 There 
were 599,211 assembled reads generated from the 46 samples. The mean read depth is 13,026 (ranged from 
3700 to 29,332) and the standard derivation of read depth is 6099. Multivariate trees were plotted using 
Tree of Life v1.0. 260 To normalize the sequence depth of each sample, 3700 reads were randomly picked 
from each sample for alpha diversity analysis, 51 OTUs were hence removed after random rarefication for 
diversity measurement.  
 
Sequencing Data Curation for Chapter 3 
The iHMP project consists of 105 human subject who has been followed over four years period. In short, 
the participants were recruited under the Stanford University following Institutional Review Board 
Protocol #23062. Stool sample and blood sample were collected from host after a fast overnight [ref main 
paper]. Stool samples were processed according to Human Microbiome Project standard protocol (#07-
001. V12.0) as described above. Cytokine data was generated by 63-plex Luminex antibody conjugated 
bead capture assay (Affymetrix, Santa Clara, California). Raw cytokine data were normalized to eliminate 
the variation introduced by using multiple plates for the assay.  
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After we obtain microbiome 16S rRNA sequence reads count data as an OTU table and normalized 
cytokine data in Median Fluorescence Intensity (MFI), we selected time points when both microbiome 
data and cytokine data were collected and time-matched. There were 92 subjects whose measurements 
were selected for further analysis, which included 753 sample points. Participants age ranged from 25 to 
75 years old, Body Mass Index (BMI) ranged from 19.10 kg/m2 to 40.83 kg/m2, steady-state plasma 
glucose (SSPG) ranged from 40 to 276 mg/dL. According to the manufacturer’s protocol, CHEX1 to 
CHEX4 are different types of background control for Luminex MFI data. Any data points showed a 
CHEX1~4 background noise that was 5 standard derivations or more away from mean were removed. 
Among 92 subjects, 35 subjects had less than 5 time points, those subjects were hence removed for 
building the general mixture model.    
 
Statistical Analysis  
The R packages “phyloseq” and “vegan” were used for alpha diversity and beta dissimilarity analysis. 
261,262 The two-sided student’s t-test was used for significance testing of the normally distributed variables, 
otherwise the Wilcoxon signed-rank test or Mann-Whitney U test was used, depend on whether two 
samples are from the same population or independent. Chi-Square test was used to determine if the 
proportion of insulin resistance is different between Th-17 High-Activity (HA) and Th17 Low-Activity 
(LA) groups. Linear discriminant analysis based on effect size (LEfSe) 86 was performed with the web 
tool at http://galaxyproject.org/. The statistical tests were performed using R (version 3.5.0). Plots were 
generated with either R program “ggplot2” and “cowplot” package263-265 or Graph-Pad Prism version 6.00 
for Mac. (GraphPad Software, La Jolla, California, USA)  
Data Modelling: Mixture model of Th17 group  
Subjects sampled more than five times were included in the General Mixture Model (GMM) as described 
above. The longitudinal IL-17A, IL-17F and IL-22 MFI data were summarized as mean value and SD for 
87 
 
each individual, and then scaled in R. To determine the optimal number of Gaussian distributed clusters, 
models with 1~9 clusters were evaluated using the Bayesian Information Criterion (BIC), resulting in 
three clusters selected for further analyses. Cluster #1 was comprised of 25 subjects (Th17 LA group), 32 
to cluster #2 (Th17 Indeterminate-Activity (IA) group) and 11 to cluster #3 (Th17 HA group), the mixing 
probability of each cluster was 0.3634941, 0.4749886, and 0.1615172, respectively. Participants assigned 
to each cluster were associated with a “confidence of assignment” probability (0%~100%); those samples 
with less than 99% confidence to be assigned to any group (6 individuals in total) were removed from the 
subsequent analyses.   
 
Data Modelling: Linear Mixed Model  
R package “lme4” 266 was used to build and execute the Linear Mixed Model. The model was built 
separately to test different hypothesis as described below.   
 
To test if metabolic profiles were different among three groups, the equation we used was:  
 
Target of Interest ~ Group + Days + Gender + BMI + Adj.age + (1|Subject_ID) 
 
Fixed effects included Group as the categorical variable derived from the GMM model, Gender was a 
binary categorical variable, Body Mass Index (BMI) and adjusted age (Adj.age) were continuous 
variables. Days was a numerical measurement of how many days after the overall study start date the 
sample was collected. Adjusted age described the average age of an individual during the study period. 
Random effects included a random intercept for each subject (1|Subject_ID).  
 
For RDW, to adjust the previous known effect of Mean Corpuscular Hemoglobin (MCH) and Mean 
corpuscular volume (MCV) on the readout of RDW222, the model was built as  
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RDW ~ Group + Days + MCH + MCV + Gender + BMI + Adj.age + (1|Subject_ID) 
 
For analysis related to microbiome alpha diversity and Firmicutes/Bacteroidetes Ratio, we simply would 
like to understand the fixed effect in this mixed model, so the model is built as  
 
Microbiome Diversity (or F/B ratio) ~ Group+ Gender + BMI + Adj.age  + (1|Subject_ID) 
 
Bayesian Mixed-Effects Model for Taxa and Cytokine interactions conditional on cluster 
assignment   
A Bayesian negative binomial longitudinal mixed effects model was used to evaluate the relationship 
between individual microbes and cytokines. Each microbe was modeled as the response variable with a 
random intercept for each subject, and with fixed effects for time, and an interaction term for the cluster 
identity (defined by the GMM, described above) and the cytokine of interest, thereby evaluating whether 
the relationship between a microbe and cytokine pair differed depending on the identity of the cluster. 
This followed standard matrix notation:  
 
Mi ~ Xiβ+Zibi+ εi 
 
Where Mi is a vector of microbe relative abundances for each subject i, Xi is the matrix of fixed effects, Zi 
is the random effects vector of 1’s denoting a random intercept, bi is a scalar for each subject, and εi is a 
zero-centered error term. The fixed-effects matrix Xi is comprised of the days post study start Di, and an 
interaction term for cluster (Ci) and cytokine (Yi).  
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Sampling was performed with four chains with 5000 iterations per sample, and a burn-in of 1000 
iterations. Samples were drawn using a No-U-Turn Sampler implemented in the “brms” package267-269. 
Chain convergence was confirmed by visual inspection of iteration plots and posterior predictive 
distributions.   
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Appendix II: Impact of Age, Caloric Restriction, and Influenza Infection on 
Mouse Gut Microbiome: An Exploratory Study of the Role of Age-Related 
Microbiome Changes on Influenza Responses 
The following is a duplicate version of the article published in Frontiers in Immunology and reprinted 
with permission under https://creativecommons.org/licenses/by/4.0/ 
 
Jenna M. Bartley*, Xin Zhou*, George A. Kuchel, George M. Weinstock, Laura Haynes. Impact of Age, 
Caloric Restriction, and Influenza Infection on Mouse Gut Microbiome: An Exploratory Study of 
the Role of Age-Related Microbiome Changes on Influenza Response. Front Immunol. 2017; 8: 1164 
 
Abstract 
Immunosenescence refers to age-related declines in the capacity to respond to infections such as influenza 
(flu). Caloric restriction represents a known strategy to slow many aging processes, including those 
involving the immune system. More recently, some changes in the microbiome have been described with 
aging, while the gut microbiome appears to influence responses to flu vaccination and infection. With these 
considerations in mind, we used a well-established mouse model of flu infection to explore the impact of 
flu infection, aging, and caloric restriction on the gut microbiome. Young, middle-aged, and aged caloric 
restricted (CR) and ad lib fed (AL) mice were examined after a sublethal flu infection. All mice lost 10–
20% body weight and, as expected for these early time points, losses were similar at different ages and 
between diet groups. Cytokine and chemokine levels were also similar with the notable exception of IL-1α, 
which rose more than fivefold in aged AL mouse serum, while it remained unchanged in aged CR serum. 
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Fecal microbiome phyla abundance profiles were similar in young, middle-aged, and aged AL mice at 
baseline and at 4 days post flu infection, while increases in Proteobacteria were evident at 7 days post flu 
infection in all three age groups. CR mice, compared to AL mice in each age group, had increased 
abundance of Proteobacteria and Verrucomicrobia at all time points. Interestingly, principal coordinate 
analysis determined that diet exerts a greater effect on the microbiome than age or flu infection. Percentage 
body weight loss correlated with the relative abundance of Proteobacteria regardless of age, suggesting flu 
pathogenicity is related to Proteobacteria abundance. Further, several microbial Operational Taxonomic 
Units from the Bacteroidetes phyla correlated with serum chemokine/cytokines regardless of both diet and 
age suggesting an interplay between flu-induced systemic inflammation and gut microbiota. These 
exploratory studies highlight the impact of caloric restriction on fecal microbiome in both young and aged 
animals, as well as the many complex relationships between flu responses and gut microbiota. Thus, these 
preliminary studies provide the necessary groundwork to examine how gut microbiota alterations may be 
leveraged to influence declining immune responses with aging. 
 
Keywords: aging, influenza, gut microbiome, caloric restriction, cytokines 
 
Introduction 
Aging is a complex process that has dramatic impacts on most systems in the body. 270 This is especially 
true of the immune system where significant age-related changes are observed in both innate and adaptive 
immune responses. One of the most prominent manifestations of aging is an increase in susceptibility to 
infections. In fact, influenza infection is one of the top killers of elderly people in the world, with the oldest 
being most at risk. 271,272  In aging mouse models, the clearance of influenza virus is slower and T cell 
responses are reduced and delayed when compared to young mice, which closely mirrors what happens 
during influenza infection of elderly humans. 273-276 In addition, our recent study demonstrated that there 
are lingering inflammatory cytokines such as IL-6, IL-1α, and G-CSF in the bronchiolar lavage fluid (BAL) 
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of aged mice during influenza infection. We have also shown that there is an increasing level of albumin in 
the BAL of aged mice, which is indicative of lung damage during the later stages of infection. 277 These 
results indicate that the inability to efficiently clear virus in aged lungs corresponds to extended 
inflammation and lung damage.  
 
One of the most consistent ways to delay aging in mice is via caloric restriction (CR). Indeed, CR was first 
shown to extend the lifespan of rodents in the 1930s 278 and has since been observed across multiple species, 
ranging from invertebrates to rodents to even some non-human primate studies; 279-282 however, it is 
important to note that this is not observed in all studies 283 284 285 286 287 288 suggesting some mechanisms of 
longevity with CR may not be conserved among species and that details of implementation likely effect 
outcomes. Despite these discrepancies, and more importantly, along with extending lifespan, CR has been 
shown to delay age-related deficits in multiple physiological systems in mice, 289-294 seemingly targeting 
the process of aging itself. From a translational perspective, human CR studies assessing longevity are 
nearly impossible, and short-term studies evaluating other health span measures are difficult to control and 
criticized for practicality (please refer to Ref. 295 for a recent review of human CR trials). Regardless of 
these limitations, results from the both population studies, 296 as well as the Comprehensive Assessment of 
Long-term Effects of Reducing Intake of Energy 297,298,299 and Caloric Restriction with Optimal Nutrition 
300,301 studies show benefits in some areas, albeit not in all aspects of CR in rodent trials, suggesting CR 
does hold value within human aging research. Moreover, the benefits to multiple different systems evident 
in rodent studies makes it an attractive avenue to pursue. It is important to note that CR in these cases is not 
malnutrition (although feed is generally reduced by 40% caloric content, it is fortified with micronutrients 
to prevent deficiencies), and it is normally introduced after mice have reached maturation. There are many 
hypotheses for the mechanism of action of CR, including modulation of glucose–insulin homeostasis, 
growth hormone axis, autophagy changes, and alteration of inflammatory pathways; however, it is likely 
many of these changes may act in concert to delay aging. Nonetheless, CR has consistently shown 
improvement in multiple facets of aging, including delaying immunosenescence. 302,303,304 ,305,306 Most 
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notably, CR attenuates the shift from naive to memory phenotype observed in T cells with aging 307 and 
maintains the proliferative capacity of T cells. 308,309 Despite these positive effects on the aged immune 
system, the effects of CR on immune responses to influenza with aging is not clear. Original studies by 
Effros et al. 310 demonstrated that CR could enhance the immune response in aged mice ameliorating age-
related declines in T cell proliferation and antibody production in response to intraperitoneal immunization 
to influenza. Conversely, work from Gardner and colleagues 311-314 demonstrated increased severity of 
infection in aged CR mice with increased viral titers and mortality in response to intranasal influenza 
infection attributed to impaired NK cell responses 312,313 and/or reduced energy reserves and lethal weight 
loss. 315 However, in these studies, high doses of influenza were utilized with mortality even observed in 
young mice; thus, it is unclear how CR modulates the immune response to more sublethal doses of influenza. 
 
More recently, the importance of the microbiome in regulating immune responses has been elucidated. The 
gut microbiota has regulatory effects on not only intestinal immunity but also systemic immune responses 
316 and systemic T cell subset populations can be skewed by different microbiota predominance. 91,317-319 
Further, pulmonary immunity is directly affected by the gut microbiota with regards to both allergic airway 
320 and infectious disease 321,322 responses. Importantly, the gut microbiota plays a major role in mediating 
flu infection-related immune responses and is particularly crucial for respiratory tract DCs migration, T cell 
priming, cytokine secretion, and overall viral clearance. 321 Dysbiosis of the gut microbiota induced by 
antibiotic administration during flu infection influences helper T cell responses and can negatively impact 
flu outcomes and recovery. 323 In addition, influenza infection itself induces gut microbiota dysbiosis 
through type I interferons (IFN-I) favoring Proteobacteria overgrowth. 230 Thus, the relationship between 
gut microbiota and influenza infection seems complex and integrated. 
 
Furthering this line of thought, the gut microbiome also changes with age [recently reviewed in Ref. 165,324]. 
More specifically, there seems to be a general decrease in microbiota diversity with aging, 160,325 as well as 
an increase in Proteobacteria abundance and lower levels of Firmicutes. 143,160,325-327 Also, a shift toward a 
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more Bacteroidetes dominated microbiome was associated with frailty. 143 It is unknown how these changes 
to gut microbiota with aging may influence immune responses. CR also impacts the microbiome with 
greater levels of Lactobacillus and other potential probiotics associated with longevity. 328 But importantly, 
the influence of gut bacteria microbiota changes on age-related pathologies has yet to be determined. It is 
possible that gut microbiota changes with CR may be a potential mechanism of longevity and/or related to 
some of the “antiaging” effects evident in many murine studies. 
 
It is known that different components of nutrition can affect the aged immune system 329 and that 
prebiotic/probiotic supplementation may decrease the severity of infection in the elderly. 330-333 Moreover, 
small-scale studies have indicated that specific probiotics and prebiotics may improve flu vaccine response 
in hospitalized elderly 334-336 suggesting that age-related alterations in gut microbiota may precipitate 
reduced flu responses in the elderly, and that this dysbiosis can be treated to improve immune responses. 
Indeed, depletion of specific gut microbiota through antibiotic treatment can negatively affect both DC 321 
and T cell 321,323 influenza immune responses, while the gut microbiota itself is affected by influenza 
infection through type I interferons (IFN-I), 230 thus the relationship between gut microbiota and influenza 
infection is bidirectional and warrants further investigation.  
Here, in this exploratory study, we sought to examine how CR, a known modulator of aging and gut 
microbiota, can influence influenza induced gut microbiota changes and immune responses during acute 
influenza infection in young, middle, and aged C57BL/6 mice. We hypothesized that CR would protect 
aged mice from age-related gut microbiota changes and thus mitigate influenza induced changes to gut 
microbiota and improve immune responses. 
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Materials and Methods  
Mice  
Young (5–6 months old), middle (9–10 months old), and aged (19–21 months old) caloric restricted (CR) 
and ad libitum (AL) C57BL/6 male mice from the National Institute on Aging caloric restricted rodent 
colony were obtained at least 6 weeks prior to experimentation to allow appropriate acclimation to our 
facility. CR mice were fed the NIH31 fortified diet with CR was initiated at 14 weeks of age at 10% 
restriction, increased to 25% restriction at 15 weeks, and to 40% restriction at 16 weeks where it was 
maintained throughout the life of the animal. AL mice were fed the NIH31 diet for their entire life. All mice 
were singly housed in a climate controlled environment with 12:12 light: dark cycle and water was provided 
ad libitum. For all analyses, 2–3 mice per group were analyzed. Due to the closing of the NIA caloric 
restricted rodent colony, we were unable to obtain more mice for experiments and thus the results presented 
are preliminary insights into the ability of CR to modulate gut microbiota and influenza responses with 
aging. All procedures were approved by the University of Connecticut School of Medicine Institutional 
Animal Care and Use Committee and carried out in accordance with these regulations. All mice underwent 
gross pathological examination at time of sacrifice and animals with obvious pathology were excluded from 
the study. 
 
Viral Infection and Analysis 
To infect with Influenza virus A/PR/8/34 (PR8), 400 EID50 were given intranasally in 40 µl to isoflurane 
anesthetized animals. Mice were sacrificed 7 days post infection. Lungs were harvested and the viral burden 
in mRNA from digested whole lung tissue was determined by real-time PCR measuring influenza 
polymerase acidic protein gene (PA) copy number. 256,337 BAL was collected by flushing lungs with 1 ml 
saline. BAL and serum were assayed for cytokine and chemokine content using the Luminex Mouse 
Cytokine/Chemokine 32-plex panel (EMD Millipore, Billerica, MA, USA). Stool Collection and 
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Microbiome Analysis Fecal samples were collected between 6:00 a.m. and 7:00 a.m. in the morning each 
day beginning 3 days prior to infection (day −3) and stored at −80°C immediately after collection for 
microbiome analysis. A total number of 187 samples were collected. Total DNA was extracted from fecal 
samples by using Power Soil DNA Extraction kit (Mo Bio Laboratories, Carlsbad, CA, USA) per 
manufacturer’s protocol. Bacterial 16S ribosomal RNA gene was amplified by using the 27F/534R primer 
set (27F 5′-AGAGTTTGATCCTGGCTCAG-3′, 534R 5′-ATTACCGCGGCTGCTGG-3′). PCR reactions 
were performed using phusion high-fidelity PCR Mastermix (Invitrogen, Carlsbad, CA, USA) with the 
following condition: 95°C for 2 min (1 cycle), 95°C for 20 s/56°C for 30 s/72°C for 1 min (30 cycles). PCR 
products were purified using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA) according 
to manufacturer’s protocol. Library was prepared with Illumina’s instruction specifically for Miseq 
platform. 17 samples failed the DNA extraction and sequencing library preparation. Full microbiome data 
are available at https://www.ncbi.nlm.nih.gov/bioproject/PRJNA393321.  
 
Statistical Analysis 
Weight loss and cytokine/chemokine parameters were analyzed via two-way ANOVA with Bonferroni post 
hoc corrections (GraphPad Prism, GraphPad Software, Inc., La Jolla, CA, USA). Raw sequencing reads 
were assembled using FLASH. 256 Chimeric sequences were removed using USEARCH. 257 Operational 
taxonomic units (OTUs) were generated at ≥97% sequence similarity. Taxonomic assignment of OTUs was 
performed by comparing sequences to the RDP database (Confidence threshold = 50%). 60 The R package 
“phyloseq” 261 was used for alpha diversity and beta dissimilarity analysis. Relationship between microbiota 
phyla and influenza-induced weight loss and serum/BAL cytokine/chemokine concentration were analyzed 
via Spearman’s correlation using GraphPad software for Mac 6.0 (GraphPad Prism, La Jolla, CA, USA) 
and R package “corrplot”.338  
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RESULTS 
The goal of this study was to explore the interaction of aging, diet, and influenza infection with the gut 
microbiome. We aimed to gain preliminary insight into how aging may impact influenza induced 
microbiome changes, as well as how age-related microbiome changes may impact influenza responses. The 
first part of the study examined how age and CR impact the response to flu, while the second part examined 
the effect on the composition of gut microbiome. For these studies, we employed a sublethal infection dose 
and examined immune parameters at 7 days post infection. At this time point, influenza-induced weight 
loss becomes more evident, however, is not different between ages 339 or CR and AL groups (unpublished 
experiments from the Haynes lab). Thus, percent weight loss should not be a confounding factor between 
groups and should not put CR mice at greater risk to succumb to infection. 314,315 While this limits the 
observed differences between groups due to infection, it allows us to assess early time points where the gut 
microbiome may play a role. Additionally, since it is known that weight loss itself affects gut microbiota, 
340-342 this control was necessary to gain preliminary insight into influenza-induced alterations.  
 
Effect of Age and CR on the Response to Influenza Infection  
Weight loss was monitored throughout the experiment. Figure 1A shows that there were no significant 
differences in percent weight loss in any of the groups regardless of age or diet. In addition, Figure 1B 
shows that on day 7 post infection, there was no significant difference in the amount of flu virus in the lungs 
in each group. These correlate well with our previous studies showing that the main age-related differences 
in response to sublethal influenza infection are not seen during the peak of the infection during the first 
week, but become apparent during the resolution phase in week two following flu infection. 342 
 
The BAL fluid from each mouse was analyzed for cytokine and chemokine contents. As shown in Figure 
1C, there were no significant differences in cytokines important for a protective immune response to 
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influenza infection including GCSF, IFNγ, IL-1α, IL-6, and TNF. In addition, there were no significant 
differences in chemokines that recruit protective immune cells to the lungs including CCL3, CCL4, CCL5, 
CXCL1, and CXCL10. A similar pattern was also observed when the serum from these groups was analyzed 
(Figure 1D) except for a significant increase in IL-1α in the aged AL group that was not seen in aged CR 
mice. Thus, both locally in the BAL and systemically in the serum, there are few measurable differences 
between the response to infection in young, middle aged, and aged groups and between AL and CR groups 
at this relatively early time point following flu infection. 
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Appendix Figure 1
Response to influenza infection. Young, middle-aged, and aged C57BL6 mice on an ad libitum 
(AL) or caloric-restricted (CR) diet were anesthetized and infected with 400 EID50 of influenza 
virus. (A) Each day, mice were weighed and the percent of the starting weight is shown. On day 
7 postinfection, mice were sacrificed. (B) mRNA was isolated from the lungs and influenza virus 
was quantitated by real-time PCR measuring influenza polymerase acidic protein gene (PA) 
copy number. (C) Bronchiolar lavage fluid and (D) serum was collected and subjected to 
multiplex analysis to determine levels of cytokines and chemokines. Data were analyzed via 
two-way ANOVA with Bonferroni post hoc corrections; *p < 0.05.
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Effect of Age and CR on the Gut Microbiome during Influenza Infection 
It is known that gut microbiome is affected by influenza viral infection. 230 To fully understand the dynamics 
of this process and its implication, stool samples were collected prior to and during influenza infection. 
Analysis was done by reconstruction of the gut bacterial microbiome by amplicon sequencing to access the 
composition of the microbiota population. Figure 2A shows the relative abundance of nine bacterial phyla 
in each experimental group. While there are no major age-related differences apparent in phylum level, 
there are differences due to influenza infection and diet. In each age category, the distribution of phyla is 
changed by day 7 post infection in both AL and CR groups, characterized by an increase in Proteobacteria 
and Verrucomicrobia. Furthermore, Proteobacteria and Verrucomicrobia are more abundant in the CR 
groups when compared to AL in each age category. Figure 2B shows the Bray Curtis dissimilarity of 
samples indicating they segregate by diet but not by infection in each age group, this implies that diet had 
a greater impact on the composition of gut microbiome when compared to the impact of influenza infection. 
Similar to a previous report, 230 we observed increased phylum Proteobacteria in all groups at day 7 post 
influenza infection. We determined that regardless of age, the relative abundance of phylum Proteobacteria 
was positively correlated with percent body weight loss at this time in AL and CR (r = 0.8095, p = 0.0218 
and r = 0.8333, p = 0.0154; respectively, Figures 3A, B) indicating a relationship between severity of 
infection and Proteobacteria abundance. To further examine the relationship between flu pathogenicity and 
gut microbiota abundances, we examined this relationship among all groups and major OTUs. This 
approach increases the overall sample size (n = 17) to increase the power of our correlation analysis and 
provide preliminary insight into potential key bacteria associated with flu responses regardless of age and 
diet. Ten specific OTUs correlated with percent weight loss, and interestingly, Alistipes OTU_34 and 
Parabacteroides OTU_9, both members of the Bacteroidetes phyla showed the strongest relationship (r = 
0.8235, p < 0.0001 and r = 0.7672, p = 0.0005; respectively, Figures 3C,D), while another Bacteroidetes, 
Hallella OUT_11 was the next strongest relationship, however, was negatively correlated with percent 
weight loss (r = −0.5907, p = 0.0216, Figure 3E); highlighting differential relationships within phyla.  
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Appendix Figure 2
(A) Relative abundance of nine phyla at 0, 4, and 7 day postinfection (dpi) 
in young, middle, and aged ad libitum (AL) or caloric-restricted (CR) mice. 
For middle-aged CR group, we do not have data at 7 dpi, so 6 dpi is shown 
here instead. Relative abundance of bacteria is shown as a fraction. (B) 
PCoA plot of Bray Curtis dissimilarity prior to (naïve, −3–0 dpi) and after 
(postinfection, 4–7 dpi) flu infection.
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Next, we examined the relationship between serum cytokine/chemokines and major OTUs observed among 
all groups to determine how influenza-induced inflammation relates to bacterial abundances (Figure 4). We 
observed 22 significant correlations between relative bacterial abundance and inflammatory mediators in 
the serum. Of note, CXCL1 was positively correlated with unclassified Lachnospiraceae OTU_12, 
Alistipes OTU_26, and Bacteroides OTU_29, CCL2 was positively correlated with Parabacteroides 
OTU_9, Alistipes OTU_34, and Unclassified Clostridiales OTU_25, and TNFα was positively correlated 
with unclassified alpha-Proteobacteria OTU_2, Butyrivibrio OTU_28, Unclassified Clostridiales OTU_30, 
and Lachnospiraceae incertae sedis OTU_37. Conversely, CXCL10 was negatively correlated with 
Unclassified Porphyromonadaceae OTU_1 and Parasutterella OTU_18, and CCL5 is negatively 
correlated with Barnesiella OTU_3, Butyrivibrio OTU_28, Unclassified Porphyromonadaceae OTU_27, 
Allobaculum OTU_35, and Anaerostipes OTU_40. Among those correlations we observed, the three 
strongest positive correlations were CXCL1 with Bacteroides OTU_29, CCL2 with Parabacteroides 
OTU_9, and CCL2 with Alistipes OTU_34. The three strongest negative correlation were CCL3 with 
Prevotella OTU_8, CCL5 with Unclassified Porphyromonadaceae OTU_27, and CCL5 with Butyrivibrio 
OTU_19. Thus, systemic immune responses were related to gut microbiota alterations. Interestingly, aside 
from Butyrivibrio, the strongest correlations, both positive and negative, were Bacteroidetes. Though it is 
not possible to conclude any causal relations between these bacteria taxa and the correlated host response, 
these findings provide insight into future research in manipulating bacterial gut microbiome to facilitate 
antiviral immune responses. 
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Appendix Figure 3
The percent weight loss for AL (A) and caloric restricted (B) at 7 days post infection (dpi) is 
plotted against the relative abundance of phylum Proteobacteria (after log2 transform). 
Correlation of relative abundance of Alistipes OTU_34 (C), Parabacteroides OTU_9 (D), and 
Hallella OTU_11 (E) with percent weight loss among all groups is shown. The bacteria 
abundance is the average of 5, 6, and 7 dpi. Spearman’s correlation with p < 0.05.
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Appendix Figure 4
Correlation of operational taxonomic units (OTUs) relative abundance with serum cytokines at 7 day 
post infection (dpi). OTUs relative abundance is the average of 5, 6, and 7 dpi. Color intensity and 
size are proportional to the spearman correlation coefficient (p < 0.05). Positive correlations are 
displayed as blue and negative correlations are displayed in red. UC: unclassified according to RDP 
database (confidence threshold = 50%).
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DISCUSSION 
In this exploratory study, we sought to obtain preliminary information as to how CR, a known modulator 
of aging and gut microbiota, could influence influenza-induced gut microbiota changes and immune 
responses during acute influenza infection in young, middle aged, and aged mice. Different outcomes of 
influenza infection, due to the influence of aging and CR, could be mediated by modulation of the gut 
microbiota by these factors with subsequent effects of infection due to the different microbial communities. 
We observed that CR affected the gut microbial communities (Figure 2), as found in previous studies, and 
that age also has an effect (the different patterns in Figure 2B). However, no obvious effect of infection was 
observed (Figure 2). 
 
Unlike previous studies, 310,314 we did not observe significant differences in weight loss or viral burden 
following influenza infection in CR aged animals. However, our study differed in that we utilized a 
sublethal dose of influenza and sacrificed mice at a relatively early point of infection, and both of these 
could contribute to a lessening of the effect of infection on the microbiome.  
 
Although there was not a large effect on microbial community structure following infection, we did observe 
an increase in the proportion of Proteobacteria, which was more significant in CR mice but independent of 
age (Figure 2A). The increase in the proportion of Proteobacteria was correlated with weight loss (Figure 
3), taken as a marker of infection severity. This again was independent of age. Further, multiple OTUs 
correlated with weight loss from the Bacteroidetes phylum. This connection raises the possibility that a 
change in the microbiome has a connection with infection outcome, as hypothesized above; however, the 
relationship does not seem to be straight forward and members of the same phyla have differential 
relationships. Future research can examine if elimination or transfer of these specific bacteria can impact 
flu responses. Indeed, others have shown antibiotic treatment is detrimental to flu immune responses, 
specifically oral neomycin eliminated Gram-positive bacteria and impaired immune responses. 321 Here, we 
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identify Gram-negative bacteria that may also be crucial for immune responses. The PR8 strain of influenza 
virus used for these studies will not directly infect gut tissue of B6 mice, 229 raising the question of how a 
respiratory infection can affect the gut microbiome. The mucosal surfaces in lung and gut are considered a 
common mucosal surface that share immunological signals, 343 so inflammation from one site is likely to 
affect the other site. Since Proteobacteria are generally observed during gut inflammation, 344 the more 
severe infection in the lung, the greater the effect on the gut, and this would result in the observed correlation 
between Proteobacteria (a measure of inflammation in the gut) and weight loss (a measure of infection). 
Finally, we note that overgrowth of Proteobacteria can be impaired by blocking the type I interferon (IFN-
I) signal, 160 suggesting this gut microbiota change correlated with lung inflammation is mediated by an 
IFN-I-related immune response. 
 
The gut is believed to be the largest immunological compartment in the body 345 and thus signaling from 
the gut microbiome may play an important role in viral infections. For example, mouse mammary tumor 
virus 346 and Enteric virus 347 require intestinal bacterial flora to establish effective infection. Lymphocytic 
choriomeningitis virus and influenza virus, 348 conversely, will trigger a more effective immune response if 
intestinal bacterial flora is present. Also, germ-free mice, 349 mice treated with an antibiotic cocktail, 321 or 
TLR5 KO mice (with impaired function in sensing bacterial flagellin) 95 will not generate adequate immune 
response to influenza viral infection. Thus, the microbiome helps protect during flu infection. Although 
here we show a correlation between Proteobacteria abundance and infection, each member of the microbiota 
may signal the immune system in a different manner. 350 For example, a previous report 321 showed that a 
host with antibiotic treatment to largely deplete Lachnospiraceae would not generate a good antibody 
response against trivalent inactivated influenza vaccine. Similarly, we noticed that higher relative 
abundance of genus Lachnospiraceae OTU_12 and OTU_32 are correlated with higher amount of CXCL1 
and IL-1α, respectively. More generally, we show here that cytokine production associated with flu 
infection in our study correlates differently for each of 22 OTUs (Figure 4). This suggests that members of 
the microbiome regulate the immune response in different ways. 
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These preliminary findings contribute to the understanding of dynamics and complexity of gut bacterial 
microbiota and influenza infection. We are the first to show the early changes (Day 4 post influenza 
infection) of gut bacterial microbiota composition in both young, middle, and aged mice on both AL or CR 
diet. Interestingly, though CR had a great impact on gut microbiota, it did not seem to affect flu-induced 
immune responses or flu-induced alterations in the gut microbiota at these early time points. It is possible 
that these alterations, such as increased proteobacteria compared to AL mice, may have effects at later time 
points in flu responses and recovery. More research is necessary to determine if CR modulation of gut 
microbiota with aging is beneficial to flu immune responses. Cytokine production associated with influenza 
infection in our study correlates differently with each OTUs. Although the data we present do not allow 
causal relations between bacteria and cytokine production to be determined, they do provide hypotheses for 
virus-bacterial interactions through the immune system. There is evidence that the genus Lactobacillus can 
improve the immune response to the PR8 strain of influenza 351,352 and respiratory syncytial virus 353 
infection. Here, we find multiple members of the Bacteroidetes phyla to be correlated with immune 
parameters and flu pathogenicity. Thus, while influenza infection promotes Proteobacteria overgrowth 
through IFN-I, 230 members of the Bacteroidetes phyla are also affected and likely in turn affect immune 
parameters, both positively and negatively. Interestingly, a Bacteroidetes dominated microbiome was 
associated with increased frailty among the elderly, 143 perhaps suggesting a microbiota link associated with 
the increased disability observed following influenza infection in the elderly. 354 Future research should 
explore manipulation of bacterial species from these phyla to modulate flu immune responses. Thus, we 
believe this exploratory study can provide some additional guidance to the use of microbiota to facilitate 
virus-specific immune responses, especially for elderly whose immune responses are known to be deficient. 
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